AU2012262581A1 - Polymorphism panels predictive of anthracycline-induced cardiotoxicity (ACT) - Google Patents

Abstract

Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more such polymorphisms is indicative of susceptibility to the development of cardiotoxicity.

Description

WO 2012/162812 PCT/CA2012/000529 POLYMORPHISM PANELS PREDICTIVE OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY (ACT) FIELD OF TILE INVENTION This invention relates to the field of genetic markers for adverse drug reactions. More specifically, methods useful for identifying individuals that may be at risk for an adverse drug reaction. BACKGROUND Anthracycline-induced cardiotoxicity (ACT) is one of the most important adverse drug reactions in childhood cancer therapy with potential life-long consequences causing substantial morbidity and mortality as well as limiting anthracycline use (Mertens, A.C. et al. J Clin Oncol (2001) 19:3163-3172; van Dalen, E.C. et al. Eur J Cancer (2006) 42:3191-3198; and Lipshultz, S.E. Heart (2008) 94:525-533). Nevertheless, anthracyclines are widely used - nearly 60% of childhood cancer patients receive anthracyclines, and help to improve cancer survival rates (van Dalen, E.C. et al. Eur J Cancer (2006) 42:3191-3198). ACT is a serious adverse drug reaction (ADR) of cancer therapy, and is, in part, mediated by genetic variation. Recently, several genetic variants predictive of ACT risk in children were identified and replicated. ADRs are a significant cause of illness, hospitalization and death for both children and adults in the Western world (LAZAROU et al JAMA 1998; PIRMOHAMED et al, BMJ 2004). Estimates suggest that 15% of hospitalized children experience an ADR. Those that do survive the ADR may be left disabled (MITCHELL et al., 1988 Pediatrics 82:24-9; MARTINEZ-MIR et al., 1999. Br J Clin Pharmacol 47 :681-8). Cardiotoxicity can occur early - during or within one year after therapy - or one or many years after treatment (late cardiotoxicity) (Lipshultz, S.E. Heart (2008) 94:525-533). It manifests as asymptomatic subclinical left ventricular dysfunction - usually diagnosed using echocardiography - in up to 57% of patients, and which can be progressive (Kremer, L.C. et al. Ann Oncol (2002) 13:819-829; Lipshultz, S.E. et al. J Clin Oncol (2005) 23:2629-2636; and van der Pal, H.J. et al. Arch Intern Med (2010) 170:1247 1255), or as severe clinical heart failure requiring treatment in as high as 16% (van Dalen, E.C. et al. Eur J Cancer (2006) 42:3191-3198; Lefrak, E.A. et al. Cancer (1973) 32:302-314; Von Hoff, D.D. et al. Ann Intern Med (1979) 91:710-717; and Kremer, L.C. et al. Ann Oncol (2002) 13:503-512). Identification of patients at risk for ACT is important to allow for risk stratification and to inform treatment and monitoring options. Many clinical risk factors for ACT have been identified, most notably higher cumulative anthracycline doses and concomitant cardiac irradiation, with some of these known for 1 WO 2012/162812 PCT/CA2012/000529 decades (Tukenova, M. et al. J Clin Oncol (2010) 28:1308-1315). More recently, several studies have started to unravel the genetic susceptibility to ACT - including in children - though only few variants have been replicated in independent cohorts (Blanco, J.G. et al. Cancer (2008) 112:2789-2795; Rajic, V. et al. Leuk Lymphoma (2009) 50:1693-1698; Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011; and Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011). Many approved drugs used in children are untested in pediatric populations. While it is known that children metabolize drugs differently than adults, in many cases pediatric dosage forms are not available. This is of particular concern with chemotherapy drugs, which may frequently be supplied as a single-dose package, and in combination with other agents, excipients and the like. Pediatric populations also represent a more varied population, and this increased variability may be due to developmental differences in the normal expression of drug metabolism genes. Genetic factors are involved in variability in drug response - ranging from 20-95% in some studies. Age, sex, body weight, health, medical history and the like may be accounted for, but patient genotype is largely an unknown factor (EVANS et al 2003. NEJM 348:538-549; WEINSHILBOUM 2003. NEJM 348:529-537). Anthracyclines are used as cytotoxic agents in chemotherapeutic protocols in both children and adults, for a variety of neoplasms. Examples of anthracyclines and anthracycline analogues include daunorubicin, doxorubicin, idarubicin and epirubicin. For example, anthracyclines may be used in the treatment of solid and hematologic cancers, such as breast cancer, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma. Cardiotoxicity is a serious problem in patient populations receiving anthracyclines, particularly pediatric patients (LIPSHULTZ 2006. Seminars in Oncology 33:S8-S14). Anthracycline-induced cardiotoxicity may result in cardiomyopathy and congestive heart failure and may be irreversible. Anthracycline induced cardiotoxicity may be characterized by reduced ventricular wall thickness and mass, indicative of decreased cardiac muscle and depressed ventricular contractility. As mentioned, an increased dose, cumulative dose, nature of the particular anthracycline, administration route, age, sex and prior radiation treatment may affect onset and severity of cardiotoxicity. Administration of dexrazoxane may be beneficial in preventing or reducing cardiac injury during chemotherapy. However, the administration of enalapril, or antioxidants such as vitamin E, coenzyme Q10, carnitine, or glutathione, for example may 2 WO 2012/162812 PCT/CA2012/000529 also be beneficial in preventing or reducing cardiac injury during chemotherapy. Other agents that may be administered to reduce anthracycline cardiotoxicity are described (WOUTERS et al 2005. Br. J Hematol 131:561-578). Dose limits have been empirically set in the clinic, above which the cardiotoxicity is deemed to be unacceptable. Subclinical and clinical cardiotoxicity may occur below these doses (JOHNSON 2006. Seminars in Oncology 33:S33-70) and affect current and subsequent therapeutic regimens. Liposomal anthracycline compositions may demonstrate reduced cardiotoxicity (EWER et al 2004. Seminars in Oncology 31:161-181). Proteomic methods have been developed for early detection of drug-induced cardiotoxicity (PETRICOIN et al. 2004. Toxicol Pathol 32:122-30). Some polymorphisms have been associated with anthracycline-induced cardiotoxicity (WOJNOWSKI et al 2005. Circulation 112:3754-3762; Blanco, J.G. et al. Cancer (2008) 112:2789-2795; Rajic, V. et al. Leuk Lymphoma (2009) 50:1693-1698; Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011); and Rossi, D. et al. Leukemia (2009) 23(6):1118-26). Genotype has been shown to alter response to therapeutic interventions. Genentech's HERCEPTIN@ was not effective in its overall Phase III trial but was shown to be effective in a genetic subset of subjects with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Similarly, Novartis' GLEEVEC@ is only indicated for the subset of chronic myeloid leukemia subjects who carry a reciprocal translocation between chromosomes 9 and 22. SUMMARY This invention is based in part on the identification that the particular nucleotide (allele) or genotype at the site of a given SNP may be associated with an increased likelihood of cardiotoxicity ('risk genotype') or a decreased likelihood of cardiotoxicity ('decreased risk genotype'). In accordance with a first embodiment, methods are provided for screening a subject having a neoplastic disease for cardiotoxicity risk, the method including: determining the identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; rs12882406; 3 WO 2012/162812 PCT/CA2012/000529 rsl2896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto, for the subject, wherein the subject may be a candidate for anthracycline administration. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs) in a biological sample from the subject: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and b) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) obtaining a biological sample from the subject; b) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and c) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a first embodiment, methods are provided for screening a subject having a neoplastic disease for cardiotoxicity risk, the method including: determining the identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto, for the subject, wherein the subject may be a candidate for anthracycline administration. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs) in a biological sample from the subject: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and b) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. 4 WO 2012/162812 PCT/CA2012/000529 In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) obtaining a biological sample from the subject; b) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; and rs17583889; one or more polymorphic sites in linkage disequilibrium thereto from the sample; and c) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a first embodiment, methods are provided for screening a subject having a neoplastic disease for cardiotoxicity risk, the method including: determining the identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs2305364; rs4982753; rs4149178; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto, for the subject, wherein the subject may be a candidate for anthracycline administration. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs) in a biological sample from the subject: rs7853758; rs885004; rs2305364; rs4982753; rs4149178; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and b) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) obtaining a biological sample from the subject; b) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs2305364; rs4982753; rs4149178; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and c) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a first embodiment, methods are provided for screening a subject having a neoplastic disease for cardiotoxicity risk, the method including: determining the identity for one or more of the 5 WO 2012/162812 PCT/CA2012/000529 following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs2305364; rs4982753; and rs4149178; or one or more polymorphic sites in linkage disequilibrium thereto, for the subject, wherein the subject may be a candidate for anthracycline administration. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs) in a biological sample from the subject: rs7853758; rs885004; rs2305364; rs4982753; and rs4149178; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and b) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. In accordance with a further embodiment, methods are provided for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method including: a) obtaining a biological sample from the subject; b) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs2305364; rs4982753; and rs4149178; or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and c) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. The method may further include determining the identity of rs 17863783 or one or more polymorphic sites in linkage disequilibrium thereto. In accordance with a further embodiment, methods are provided for determining cardiotoxicity risk from anthracycline administration, the method including: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs885004; rsl7863783; rs10426377; and rs2305364; or a polymorphic sites in linkage disequilibrium thereto, for a subject receiving or about to receive one or more anthracyclines. In accordance with a further embodiment, methods are provided for determining cardiotoxicity risk from anthracycline administration, the method comprising: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs4148808; rs17863783; rs10426377; and rs2305364; or a polymorphic sites in linkage disequilibrium thereto, for a subject receiving or about to receive one or more anthracyclines. 6 WO 2012/162812 PCT/CA2012/000529 In accordance with a further embodiment, methods are provided for determining cardiotoxicity risk from anthracycline administration, the method comprising: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs17863783; rs10426377; and rs2305364; or a polymorphic sites in linkage disequilibrium thereto, for a subject receiving or about to receive one or more anthracyclines. The method may further include determining the identity of one or both of the following two SNPs: rs4982753; and rs4149178; or one or more polymorphic sites in linkage disequilibrium thereto. The method may further include determining the cumulative anthracycline dose given to the subject and/or whether the subject received radiation therapy involving the heart region. The method may further include determining the sex of the subject or the age of the subject. The subject may preferably be female if the SNP is rs4148808 or rsl 149222. The subject may preferably be male if the SNP is rs10426377. The subject may preferably be <5.3 yrs old if the SNP is rs17583889. In accordance with a further embodiment, uses are provided for the manufacture of a medicament comprising an anthracycline compound having a cardiotoxicity risk for the treatment of a subject, where the subject is a candidate for anthracycline administration, and wherein the subject treated has a reduced cardiotoxicity risk genotype at one or more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628. In accordance with a further embodiment, uses are provided for an anthracycline compound having a cardiotoxicity risk for the treatment of a subject, wherein the subject treated has a reduced cardiotoxicity risk genotype at one or more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628 for the subject, where the subject is a candidate for anthracycline administration. The subject may also have a reduced cardiotoxicity risk genotype at rsl 7863783 or one or more polymorphic sites in linkage disequilibrium thereto. In accordance with a further embodiment, there is porivded an anthracycline for use in treating a neoplastic disease in a subject in need there of, the method comprising: (a) selecting a subject having a 7 WO 2012/162812 PCT/CA2012/000529 reduced risk of developing cardiotoxicity, wherein cardiotoxicity is based on the identity of a single nucleotide polymorphism (SNP) at one or more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto; and (b) administering said subject one or more anthracyclines. The subject may also be selected based on a reduced cardiotoxicity risk genotype at rsl7863783 or one or more polymorphic sites in linkage disequilibrium thereto. In accordance with a further aspect of the invention, there is provided a method of selecting a therapeutic regimen for a subject, the therapeutic regimen including one or more opioids, the method including: determining the identity of a single nucleotide polymorphism (SNP) at one or more of the following polymorphic sites: rs7853758; rs17863783; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628, for the subject to assess the risk of toxicity. The anthracycline may be selected from one or more of the following: anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), doxorubicin, idarubicin, epirubicin, mitoxantrone, carminomycin, esorubicin, quelamycin, aclarubicin, esorubicin, zorubicin, pirarubicin, amrubicin, iododoxorubicin, detorubicin, marcellomycin, rodorubicin, and valrubicin. Alternatively, the anthracycline may be selected from one or more of the following: doxorubicin, and daunorubicin. The method may further include administering the anthracycline in accordance with the subject's risk of developing cardiotoxicity. The method may further include administering a cardioprotective agent. The method may further include administering an anthracycline that has a reduced toxicity risk associated therewith. The method may further include monitoring the subject for signs of cardiotoxicity. The cardiotoxicity risk allele may be selected from one or more of: rs7853758G; rs885004G; rs17863783A (reverse); rsl7863783T (forward); rsl0426377C; rs2305364A; rs4982753G (reverse); rs4982753C (forward); rs4l49178A; rs4l48808A; rs1149222G; rsl7583889A; rs4877847A; rsl 1625724T; rs12882406G; rs12896494T; and rs10426628A. The reduced cardiotoxicity risk allele may be selected from one or more of: rs7853758A; rs885004A; rsl7863783C (reverse); rs17863783G (forward); rs10426377A; rs2305364G; rs4982753A (reverse); rs4982753T (forward); rs4149178G; rs4148808G; rsl149222T; rs17583889C; rs4877847C; rsl1625724A; rs12882406C; rsl2896494C; and rs10426628G. The identity of a single nucleotide polymorphism may be determined by one or more of 8 WO 2012/162812 PCT/CA2012/000529 the following techniques: restriction fragment length analysis; sequencing; micro-sequencing assay; hybridization; invader assay; gene chip hybridization assays; oligonucleotide ligation assay; ligation rolling circle amplification; 5' nuclease assay; polymerase proofreading methods; allele specific PCR; matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy; ligase chain reaction assay; enzyme-amplified electronic transduction; single base pair extension assay; and reading sequence data. In accordance with a further embodiment, there are provided two or more oligonucleotides or peptide nucleic acids of about 10 to about 400 nucleotides that hybridize specifically to a sequence contained in a human target sequence consisting of a subject's toxicity associated gene sequence, a complementary sequence of the target sequence or RNA equivalent of the target sequence and wherein the oligonucleotides or peptide nucleic acids are operable in determining the identity of two or more polymorphism(s) in the toxicity associated gene sequence selected from of the following polymorphic sites: rs7853758; rs885004; rs17863783; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628. In accordance with a further embodiment, there are provided two or more oligonucleotides or peptide nucleic acids selected from the group: (a) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 1 having an A at position 301 but not to a nucleic acid molecule including SEQ ID NO:1 having a G at position 301; (b) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 1 having a G at position 301 but not to a nucleic acid molecule including SEQ ID NO: 1 having an A at position 301; (c) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:2 having a G at position 201 but not to a nucleic acid molecule including SEQ ID NO:2 having an A at position 201; (d) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:2 having an A at position 201 but not to a nucleic acid molecule including SEQ ID NO:2 having an G at position 201; (e) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:3 having an A at position 301 but not to a nucleic acid molecule including SEQ ID NO:3 having a C at position 301; 9 WO 2012/162812 PCT/CA2012/000529 (f) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:3 having a C at position 301 but not to a nucleic acid molecule including SEQ ID NO:3 having an A at position 301; (g) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:4 having an A at position 501 but not to a nucleic acid molecule including SEQ ID NO:4 having a C at position 501; (h) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:4 having a C at position 501 but not to a nucleic acid molecule including SEQ ID NO:4 having an A at position 501; (i) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:5 having an A at position 251 but not to a nucleic acid molecule including SEQ ID NO:5 having a G at position 251; (j) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:5 having a G at position 251 but not to a nucleic acid molecule including SEQ ID NO:5 having an A at position 251; (k) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:6 having an A at position 501 but not to a nucleic acid molecule including SEQ ID NO:6 having a G at position 501; (1) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:6 having a G at position 501 but not to a nucleic acid molecule including SEQ ID NO:6 having an A at position 501; (in) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 7 having an A at position 401 but not to a nucleic acid molecule including SEQ ID NO:7 having a G at position 401; (n) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 7 having a G at position 401 but not to a nucleic acid molecule including SEQ ID NO:7 having an A at position 401; (o) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:8 having an A at position 301 but not to a nucleic acid molecule including SEQ ID NO:8 having a G at position 301; (p) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:8 having a G at position 301 but not to a nucleic acid molecule including SEQ ID NO:8 having an A at position 301; 10 WO 2012/162812 PCT/CA2012/000529 (q) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:9 having an A at position 201 but not to a nucleic acid molecule including SEQ ID NO:9 having a C at position 201; (r) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO:9 having a C at position 201 but not to a nucleic acid molecule including SEQ ID NO:9 having an A at position 201; (s) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 10 having an A at position 301 but not to a nucleic acid molecule including SEQ ID NO:10 having a C at position 301; (t) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule including SEQ ID NO: 10 having a C at position 301 but not to a nucleic acid molecule including SEQ ID NO:10 having an A at position 301; (u) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:l 1 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 11 having a C at position 301; (v) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 11 having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 11 having an A at position 301; (w) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 12 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:12 having a T at position 301; (x) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 12 having a T at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:12 having an A at position 301; (y) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 13 having a C at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:13 having a G at position 501; (z) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 13 having a G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:13 having a C at position 501; (aa) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:14 having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 14 having a T at position 301; 11 WO 2012/162812 PCT/CA2012/000529 (bb) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 14 having a T at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:14 having a C at position 301; (cc) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having an A at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having a C, G, or T at position 501; (dd) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having a C at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having an A, G, or T at position 501; (ee) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having an G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having a C, A, or T at position 501; (ff) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having a T at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having an A, G, or C at position 501; (gg) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having an G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having an A at position 501; and (hh) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 15 having an A at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having a G at position 501. In accordance with a further embodiment, there is provided an array of oligonucleotides or peptide nucleic acids attached to a solid support, the array including two or more of the oligonucleotides or peptide nucleic acids described herein. In accordance with a further embodiment, there is provided a composition including an addressable collection of two or more oligonucleotides or peptide nucleic acids, the two or more oligonucleotides or peptide nucleic acids consisting essentially of two or more nucleic acid molecules set out in SEQ ID NO:1-15 or compliments, fragments, variants, or analogs thereof. The oligonucleotides or peptide nucleic acids described herein may further include one or more of the following: a detectable label; a quencher; a mobility modifier; a contiguous non-target sequence situated 5' or 3' to the target sequence or 5' and 3' to the target sequence. 12 WO 2012/162812 PCT/CA2012/000529 The oligonucleotides or peptide nucleic acids may further include one or more of the following: a detectable label; a quencher; a mobility modifier; a contiguous non-target sequence situated 5' or 3' to the target sequence or 5' and 3' to the target sequence. The oligonucleotides or peptide nucleic acids may alternatively be of about 10 to about 400 nucleotides, about 15 to about 300 nucleotides. The oligonucleotides or peptide nucleic acids may alternatively be of about 20 to about 200 nucleotides, about 25 to about 100 nucleotides. The oligonucleotides or peptide nucleic acids may alternatively be of about 20 to about 80 nucleotides, about 25 to about 50 nucleotides. The genotype may be determined using a nucleic acid sample from the subject. Genotype may be determined using one or more of the following techniques: restriction fragment length analysis; sequencing; micro-sequencing assay; hybridization; invader assay; gene chip hybridization assays; oligonucleotide ligation assay; ligation rolling circle amplification; 5' nuclease assay; polymerase proofreading methods; allele specific PCR; matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy; ligase chain reaction assay; enzyme-amplified electronic transduction; single base pair extension assay; and reading sequence data. A determination of whether a site is in linkage disequilibrium (LD) with another site may be determined based on an absolute r 2 value or D' value. When evaluating loci for LD those sites within a given population having a high degree of linkage disequilibrium (for example an absolute value for D' of > 0.5 or r 2 0.5) are potentially useful in predicting the identity of an allele of interest (for example associated with the condition of interest). A high degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.6 or r 2 > 0.6. Alternatively, a higher degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.7 or r 2 > 0.7 or by an absolute value for D' of > 0.8 or r 2 2 0.8. Additionally, a high degree of linkage disequilibrium may be represented by an absolute value for D' of > 0.85 or r 2 > 0.85 or by an absolute value for D' of > 0.9 or r 2 > 0.9. Two or more oligonucleotides or peptide nucleic acids may include 3 or more; 4 or more; 5 or more; 6 or more; 7 or more; 8 or more; 9 or more; 10 or more; 11 or more; 12 or more; 13 or more; 14 or more; 15 or more; 16 or more; 17 or more; 18 or more; 19 or more; or 20 or more. Sequence variations may be assigned to a gene if mapped within 2 kb or more of an mRNA sequence feature. In particular, such a sequence may extend many kilobases (kb) from a gene and into neighbouring genes, where the LD within a region is strong. 13 WO 2012/162812 PCT/CA2012/000529 DETAILED DESCRIPTION 1. Definitions In the description that follows, a number of terms are used extensively, the following definitions are provided to facilitate understanding of the various embodiments of the invention. An "anthracycline compound" or "anthracycline" or "anthracycline derivatives" or "anthracycline analogues" as used herein is typically an anthraquinone core attached to a carbohydrate moiety and derivative thereof (see for example, FAN et al. J. Org. Chem. (2007) 72:2917-2928; Goodman and Gilman's The Pharmacological Basis of Therapeutics 8th edition editors Alfred Goodman Gilman, Theodore Rall, Alan Nies, Palmer Taylor. Pergamon Press. 1990 pg 1241-1244). For example, include anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), doxorubicin, idarubicin, epirubicin, mitoxantrone, carminomycin, esorubicin, quelamycin, aclarubicin, esorubicin, zorubicin, pirarubicin, amrubicin, iododoxorubicin, detorubicin, marcellomycin, rodorubicin, and valrubicin. Alternatively, the anthracycline may be selected from daunorubicin and doxorubicin. As used herein "anthracycline-induced cardiotoxicity" or "ACT" is defined based on CTCAEv3 (Common Terminology Criteria for Adverse Events - see Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events- Version 3 in edition 2003) as early- or late-onset left ventricular dysfunction measured by echocardiogram (shortening fraction, SF) and/or symptoms requiring intervention. We used a more stringent threshold of SF<26% at any time during or after anthracycline therapy to better differentiate between cardiotoxicity cases and controls. To exclude transient acute cardiotoxicity, echocardiograms obtained <21 days after a dose of anthracyclines were excluded. Control patients were required to have normal echocardiograms (SF>30%) during and after therapy, with a follow-up of >5 years after completion of anthracycline therapy. Doxorubicin equivalents were used to calculate cumulative anthracycline doses (Altman A.J. editor, Children's Oncology Group. Supportive care of children with cancer: current therapy and guidelines from the Children's Oncology Group. Baltimore: Johns Hopkins University Press; 2004. 412 p.p.). "Genetic material" includes any nucleic acid and can be a deoxyribonucleotide or ribonucleotide polymer in either single or double-stranded form. A nucleotide represented by the symbol M may be either an A or C, a nucleotide represented by the symbol W may be either an T/U or A, a nucleotide represented by the symbol Y may be either an C or T/U, a nucleotide represented by the symbol S may be either an G or C, while a nucleotide represented by 14 WO 2012/162812 PCT/CA2012/000529 the symbol R may be either an G or A, and a nucleotide represented by the symbol K may be either an G or T/U. Similarly, a nucleotide represented by the symbol V may be either A or G or C, while a nucleotide represented by the symbol D may be either A or G or T, while a nucleotide represented by the symbol B may be either G or C or T, and a nucleotide represented by the symbol H may be either A or C or T. A nucleotide represented by the symbol N may be an A or G or T or C. A "polymorphic site" or "polymorphism site" or "polymorphism" or "single nucleotide polymorphism site" (SNP site) or single nucleotide polymorphism" (SNP) as used herein is the locus or position with in a given sequence at which divergence occurs. A "polymorphism" is the occurrence of two or more forms of a gene or position within a gene (allele), in a population, in such frequencies that the presence of the rarest of the forms cannot be explained by mutation alone. The implication is that polymorphic alleles confer some selective advantage on the host. Polymorphic sites have at least two alleles, each occurring at frequency of greater than 1%, and may be greater than 10% or 20% of a selected population. Polymorphic sites may be at known positions within a nucleic acid sequence or may be determined to exist. Polymorphisms may occur in both the coding regions and the noncoding regions (for example, promoters, introns or untranslated regions) of genes. Polymorphisms may occur at a single nucleotide site (SNPs) or may involve an insertion or deletion as described herein. A "risk genotype" as used herein refers to an allelic variant (genotype) at one or more of the following polymorphic sites rs7853758; rs885004; rs17863783; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; rs12882406; rs12896494; and rs10426628; or a polymorphic site in linkage disequilibrium thereto, for the subject as described herein, as being indicative of a increased likelihood of cardiotoxicity following administration of an anthracycline. The risk genotype may be determined for either the haploid genotype or diploid genotype, provided that at least one copy of a risk allele is present. Risk genotype may be an indication of an increased risk of cardiotoxicity. Subjects having one copy (heterozygotes) or two copies (homozygotes) of the risk allele are considered to have the "risk genotype" even though the degree to which the subjects is at risk cardiotoxicity may increase, depending on whether the subject is a homozygote rather than a heterozygote. Such "risk alleles" or "risk genotypes" may be selected from the following: rs7853758G; rs885004G; rsl7863783A (reverse); rsl7863783T (forward); rs10426377C; rs2305364A; rs4982753G (reverse); rs4982753C (forward); rs4149178A; rs4l48808A; rsl149222G; rsl7583889A; rs4877847A; rsl 1625724T; rsl2882406G; rsl2896494T; and rsl0426628A; or a polymorphic site in linkage disequilibrium thereto. 15 WO 2012/162812 PCT/CA2012/000529 A "decreased risk genotype" as used herein refers to an allelic variant (genotype) at one or more of the following polymorphic sites: rs7853758; rs885004; rs17863783; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs 10426628; or a polymorphic site in linkage disequilibrium thereto, for the subject as described herein, as being indicative of a decreased likelihood of cardiotoxicity following administration of an anthracycline. "Decreased risk alleles" or "decreased risk genotypes" or "reduced risk genotypes" may be selected from the following: rs7853758A; rs885004A; rsl7863783C (reverse); rsl7863783G (forward); rs10426377A; rs2305364G; rs4982753A (reverse); rs4982753T (forward); rs4149178G; rs4l48808G; rs1149222A (reverse); rs1149222T (forward); rs17583889C; rs4149178G; rs4148808G; rs1149222T; rs17583889C; rs4877847C; rsl l625724A; rsl2882406C; rs12896494C; and rs10426628G or a polymorphic site in linkage disequilibrium thereto (decreased risk alleles on the forward strand). A "clade" is a group of haplotypes that are closely related phylogenetically. For example, if haplotypes are displayed on a phylogenetic (evolutionary) tree a clade includes all haplotypes contained within the same branch. The pattern of a set of markers along a chromosome is referred to as a "Haplotype". Accordingly, groups of alleles on the same small chromosomal segment tend to be transmitted together. Haplotypes along a given segment of a chromosome are generally transmitted to progeny together unless there has been a recombination event. Absence of a recombination event, haplotypes can be treated as alleles at a single highly polymorphic locus for mapping. As used herein "haplotype" is a set of alleles of closely linked loci on a chromosome that tend to be inherited together. Such allele sets occur in patterns, which are called haplotypes. Accordingly, a specific SNP or other polymorphism allele at one SNP site is often associated with a specific SNP or other polymorphism allele at a nearby second SNP site or other polymorphism site. When this occurs, the two SNPs or other polymorphisms are said to be in Linkage Disequilibrium (LD) because the two SNPs or other polymorphisms are not just randomly associated (i.e. in linkage equilibrium). In general, the detection of nucleic acids in a sample depends on the technique of specific nucleic acid hybridization in which the oligonucleotide is annealed under conditions of "high stringency" to nucleic acids in the sample, and the successfully annealed oligonucleotides are subsequently detected (see for example Spiegelman, S., Scientific American, Vol. 210, p. 48 (1964)). Hybridization under high stringency conditions primarily depends on the method used for hybridization, the oligonucleotide length, 16 WO 2012/162812 PCT/CA2012/000529 base composition and position of mismatches (if any). High-stringency hybridization is relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high-stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and in situ hybridization. In contrast to Northern and Southern hybridizations, these aforementioned techniques are usually performed with relatively short probes (e.g., usually about 16 nucleotides or longer for PCR or sequencing and about 40 nucleotides or longer for in situ hybridization). The high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology, and examples of them can be found, for example, in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, N.Y., 1998. "Oligonucleotides" as used herein are variable length nucleic acids, which may be useful as probes, primers and in the manufacture of microarrays (arrays) for the detection and/or amplification of specific nucleic acids. Such DNA or RNA strands may be synthesized by the sequential addition (5'-3' or 3'-5') of activated monomers to a growing chain, which may be linked to an insoluble support. Numerous methods are known in the art for synthesizing oligonucleotides for subsequent individual use or as a part of the insoluble support, for example in arrays (BERNFIELD MR. and ROTTMAN FM. J. Biol. Chem. (1967) 242(18):4134-43; SULSTON J. et al. PNAS (1968) 60(2):409-415; GILLAM S. et al. Nucleic Acid Res.(1975) 2(5):613-624; BONORA GM. et al. Nucleic Acid Res.(1990) 18(11):3155-9; LASHKARI DA. et al. Proc Nat Acad Sci (1995) 92(17):7912-5; MCGALL G. et al. PNAS (1996) 93(24):13555-60; ALBERT TJ. et al. Nucleic Acid Res.(2003) 31(7):e35; GAO X. et al. Biopolymers (2004) 73(5):579-96; and MOORCROFT MJ. et al. Nucleic Acid Res.(2005) 33(8):e75). In general, oligonucleotides are synthesized through the stepwise addition of activated and protected monomers under a variety of conditions depending on the method being used. Subsequently, specific protecting groups may be removed to allow for further elongation and subsequently and once synthesis is complete all the protecting groups may be removed and the oligonucleotides removed from their solid supports for purification of the complete chains if so desired. "Peptide nucleic acids" (PNA) as used herein refer to modified nucleic acids in which the sugar phosphate skeleton of a nucleic acid has been converted to an N-(2-aminoethyl)-glycine skeleton. Although the sugar-phosphate skeletons of DNA/RNA are subjected to a negative charge under neutral conditions resulting in electrostatic repulsion between complementary chains, the backbone structure of PNA does not inherently have a charge. Therefore, there is no electrostatic repulsion. Consequently, PNA has a higher ability to form double strands as compared with conventional nucleic acids, and has a high ability to recognize base sequences. Furthermore, PNAs are generally more robust than nucleic acids. PNAs 17 WO 2012/162812 PCT/CA2012/000529 may also be used in arrays and in other hybridization or other reactions as described above and herein for oligonucleotides. An "addressable collection" as used herein is a combination of nucleic acid molecules or peptide nucleic acids capable of being detected by, for example, the use of hybridization techniques or by any other means of detection known to those of ordinary skill in the art. A DNA microarray would be considered an example of an "addressable collection". In general the term "linkage", as used in population genetics, refers to the co-inheritance of two or more nonallelic genes or sequences due to the close proximity of the loci on the same chromosome, whereby after meiosis they remain associated more often than the 50% expected for unlinked genes. However, during meiosis, a physical crossing between individual chromatids may result in recombination. "Recombination" generally occurs between large segments of DNA, whereby contiguous stretches of DNA and genes are likely to be moved together in the recombination event (crossover). Conversely, regions of the DNA that are far apart on a given chromosome are more likely to become separated during the process of crossing-over than regions of the DNA that are close together. Polymorphic molecular markers, like SNPs, are often useful in tracking meiotic recombination events as positional markers on chromosomes. Furthermore, the preferential occurrence of a disease gene in association with specific alleles of linked markers, such as SNPs or other polymorphisms, is called "Linkage Disequilibrium" (LD). This sort of disequilibrium generally implies that most of the disease chromosomes carry the same mutation and the markers being tested are relatively close to the disease gene(s). For example, in SNP-based association analysis and LD mapping, SNPs can be useful in association studies for identifying polymorphisms, associated with a pathological condition, such as sepsis. Unlike linkage studies, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. In a SNP association study the frequency of a given allele (i.e. SNP allele) is determined in numerous subjects having the condition of interest and in an appropriate control group. Significant associations between particular SNPs or SNP haplotypes and phenotypic characteristics may then be determined by numerous statistical methods known in the art. Association analysis can either be direct or LD based. In direct association analysis, potentially causative SNPs may be tested as candidates for the pathogenic sequence. In LD based SNP association analysis, 18 WO 2012/162812 PCT/CA2012/000529 SNPs may be chosen at random over a large genomic region or even genome wide, to be tested for SNPs in LD with a pathogenic sequence or pathogenic SNP. Alternatively, candidate sequences associated with a condition of interest may be targeted for SNP identification and association analysis. Such candidate sequences usually are implicated in the pathogenesis of the condition of interest. In identifying SNPs associated with cardiotoxicity, candidate sequences may be selected from those already implicated in the pathway of the condition or disease of interest. Once identified, SNPs found in or associated with such sequences, may then be tested for statistical association with an individual's prognosis or susceptibility to the condition or to the side effect of a medication. For an LD based association analysis, high density SNP maps are useful in positioning random SNPs relative to an unknown pathogenic locus. Furthermore, SNPs tend to occur with great frequency and are often spaced uniformly throughout the genome. Accordingly, SNPs as compared with other types of polymorphisms are more likely to be found in close proximity to a genetic locus of interest. SNPs are also mutationally more stable than variable number tandem repeats (VNTRs) and short tandem repeats (STRs). In population genetics linkage disequilibrium refers to the "preferential association of a particular allele, for example, a mutant allele for a disease with a specific allele at a nearby locus more frequently than expected by chance" and implies that alleles at separate loci are inherited as a single unit (Gelehrter, T.D., Collins, F.S. (1990). Principles of Medical Genetics. Baltimore: Williams & Wilkens). Accordingly, the alleles at these loci and the haplotypes constructed from their various combinations serve as useful markers of phenotypic variation due to their ability to mark clinically relevant variability at a particular position (see Akey, J. et al. Eur J Hum Genet (2001) 9:291-300; and Zhang, K. et al. (2002). Am J Hum Genet. 71:1386-1394). This viewpoint is further substantiated by Khoury et al. ((1993). Fundamentals of Genetic Epidemiology. New York: Oxford University Press at p. 160) who state, "[w]henever the marker allele is closely linked to the true susceptibility allele and is in [linkage] disequilibrium with it, one can consider that the marker allele can serve as a proxy for the underlying susceptibility allele." As used herein "linkage disequilibrium" (LD) is the occurrence in a population of certain combinations of linked alleles in greater proportion than expected from the allele frequencies at the loci. For example, the preferential occurrence of a disease gene in association with specific alleles of linked markers, such as SNPs, or between specific alleles of linked markers, are considered to be in LD. This sort of disequilibrium generally implies that most of the disease chromosomes carry the same mutation and that the markers being tested are relatively close to the disease gene(s). Accordingly, if the genotype of a first 19 WO 2012/162812 PCT/CA2012/000529 locus is in LD with a second locus (or third locus etc.), the determination of the allele at only one locus would necessarily provide the identity of the allele at the other locus. When evaluating loci for LD those sites within a given population having a high degree of linkage disequilibrium (i.e. an absolute value for r 2 > 0.5) are potentially useful in predicting the identity of an allele of interest (i.e. associated with the condition of interest). A high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.6. Alternatively, a high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.7 or by an absolute value for r 2 > 0.8. Additionally, a high degree of linkage disequilibrium may be represented by an absolute value for r 2 > 0.85 or by an absolute value for r 2 > 0.9 or by an absolute value for r 2 > 0.95. Accordingly, two SNPs that have a high degree of LD may be equally useful in determining the identity of the allele of interest or disease allele. Therefore, we may assume that knowing the identity of the allele at one SNP may be representative of the allele identity at another SNP in LD. Accordingly, the determination of the genotype of a single locus can provide the identity of the genotype of any locus in LD therewith and the higher the degree of linkage disequilibrium the more likely that two SNPs may be used interchangeably. For example, SLC28A3 rs885004 showed a high degree of LD (i.e. r 2 =0.83) with rs7853758. LD may be useful for genotype-phenotype association studies. For example, if a specific allele at one SNP site (e.g. "A") is the cause of a specific clinical outcome (e.g. call this clinical outcome "B") in a genetic association study then, by mathematical inference, any SNP (e.g. "C") which is in significant LD with the first SNP, will show some degree of association with the clinical outcome. That is, if A is associated (-) with B, i.e. A-B and C-A then it follows that C~B. Of course, the SNP that will be most closely associated with the specific clinical outcome, B, is the causal SNP - the genetic variation that is mechanistically responsible for the clinical outcome. Thus, the degree of association between any SNP, C, and clinical outcome will depend on LD between A and C. Until the mechanism underlying the genetic contribution to a specific clinical outcome is fully understood, LD helps identify potential candidate causal SNPs and also helps identify a range of SNPs that may be clinically useful for prognosis of clinical outcome or of treatment effect. If one SNP within a gene is found to be associated with a specific clinical outcome, then other SNPs in LD will also have some degree of association and therefore some degree of prognostic usefulness. Polymorphisms in linkage disequilibrium may be identified, for example, using the Haploview program (BARRETT JC. et al. Bioinformatics (2005) 21(2):263-5 (http://www.broad.mit.edu/mpg/haploview/)) and the LD function in the Genetics Package in R (R Core Development Group, 2005 - R Development 20 WO 2012/162812 PCT/CA2012/000529 Core Team (www.R-project.org). Linkage Disequilibrium between markers may be defined using r 2 whereby all SNPs available on Hapmap.org (phase II) (cohort H), all SNPs genotyped internally using the Illumina Goldengate assay (cohort I) and SNPs may be sequenced using the Sequenom Iplex Platform (cohort S) for genes of interest. A minimum r 2 of 0.5 may be used as the cutoff to identify LD SNPs. Although this study had moderate to high statistical power to replicate the previous associations, some variants were not replicated. While this might suggest that these associations were false-positive, other explanations exist. For example, the current studies were powered to find similar effect sizes, but often effects may be smaller in replication studies (Chanock, SJ. et al. Nature (2007) 447:655-660). Despite trying to keep the replication cohorts similar to the original cohorts, small differences might exist, for example in ethnicity, (supportive) treatment or follow-up, which could potentially lead to non-replication due to different effects of the variants in specific populations or subgroups (Chanock, SJ. et al. Nature (2007) 447:655-660). In the present analyses correction were made for the effects of several important clinical risk factors. Not unexpectedly, cumulative doses showed higher statistical significance in cases compared to controls in both the Dutch-EKZ and CPNDS cohort. Age at start of treatment was higher in CPNDS cases, whereas younger age was usually considered a risk factor (Kremer, LC. et al. Ann Oncol (2002) 13:503-512). This is likely in part due to the requirement in the present studies to have controls with at least a 5 year follow-up, selecting for relatively younger controls in the CPNDS cohort. Numerous sites have been identified as polymorphic sites associated cardiotoxicity following anthracycline administration (see TABLE 1). TABLE 1. Single Nucleotide Polymorphisms that Showed an Association with Anthracycline-Induced Cardiotoxicity (ACT) Gene SNP ID Chromosome SNP Alleles (* reverse ACT Predictive Symbol strand) Variant SLC28A3 rs7853758 9 A/G G SLC28A3 rs885004 9 A/G G UGT1A6 rsl 7863783 2 A/C* or G/T (forward strand) A* or T SULT2BI rs10426377 19 A/C C SLC28Al rs2305364 6 A/G A SLC22AI7 rs4982753 14 A/G* or C/T (forward strand) G* or C SLC22A7 rs4149178 6 G/A A ABCB4 rs4148808 7 A/G A 21 WO 2012/162812 PCT/CA2012/000529 ABCB4 rsl 149222 7 C/A* or G/T (forward strand) C* or G HNMT rs17583889 2 A/C A SLC28A3 rs4877847 9 A/C A SLC22A17 rsl 1625724 14 A/T T SLC22A17 rs12882406 14 C/G G SLC22A17 rs12896494 14 C/T T SULT2B1 rs10426628 A/C/G/T (where A and G are 19 most common) A TABLE 2. below shows the flanking sequences for the SNPs shown in TABLE 1 providing their rs designations and corresponding SEQ ID NO designations. Each polymorphism is identified by its position within the flanking sequence and is in bold. TABLE 2. Sequence for Cardiotoxicity-Associated Polymorphisms Listed in TABLE 1, with SEQ ID NO designations SNP SEQ Gene Alleles E Symbol SNP ID (* reverse GENOMIC SEQUENCE NO: strand) GAAGGAAGCTGGATTCTTGGGGAAGGGGCCAGGAGAGACTGACT GTCGTTGTGGGGAAGGAGGGGGATAGGAGACAGAGAAAAGGTGG GTGGGAAGTTGGGGGATGCATGAGAAGCTTCTACGGTGTGGAAG AGTCTACTGAGGTTAGGGTGGGCTGTTTACAAACCTATTTTATT T T TAAACAAAGATAGGCAGAAACAAAACAGAGGGCAGGGGCGT G ATGTGATTATACCTCAAAACTCAGCTGTGGGTAGTCAAACATGT T T CCAAACCAGGACAGGGCTGAAT TCATAAAAGACA R CAGGGCCAGGAAGGCAATCAGATTCACAGCGATGTTGGCCACCA GGGAGATGGAGGAGGATGCTCCCTGTGTTGCAGCTTCTAGAAGA TTCCCTGAATCACTTTATCAAGAAATAGCAATTCCAGAATTACC AAGGAGTTGTCAGGGGATGGACACCATTGGTGCAGAAGTAGCAT rs7853758 AATCAGAGCTTAGATAAGAGACAAACTCTAAGGCCCCTGCCTTG (at position CTCAAAATACTCACCTGAATCCCATGACATCATGAAGTGGGCAT SLC28A3 301) A/G ATGAGTATTTAACCATGTTTGTTCTTGTTTTTAAAG 22 WO 2012/162812 PCT/CA2012/000529 CTTTTATTCTAATTTGTCACAGGACTTTGACTTTTTTCCCCTGT 2 CTTCTATGGTGAGCTTTTTTTGCTCAAAGAAGGAATGAAGTTTG GGGGGATTTGTAATACCTAGATCAATACACTGAAGGCTGTCAGA AAATATTCTTGTCCTGGTGCTAAAAAGACATGGGCTTCACCACT AGTTAGCAGAGTAACCTAAGTTGA R ATAAATTGTGAGCAACCTCAGAGCCTTATTCTGAGTAGCTGTAG AGATCAGGTAAGGCATGGTAGGTGCTGACACATAGTGCCTCCTA Ctggatggcagacacacctgacagcaataacttcagcatgtcct gagaatgaccctatggtctaagcgtgtgtgtttggagttccaaa ctaaggaacctgggagcggccattccaaagattcattccttatc tataaggaatatctgaacccttggcccattccgtggaaagcagg ccatatgggggatccaggccctttgttttgggttaaatgaaggt tgggaggtggaggttgctgggggaggttactaagtgagaatgct atataaactgcctgccttttacaaacagtagcggttctcctctc tagcctgctgccactggactgccctgcatgtgagtccccctcaa taaaccctatgtctcatttgctggctccaggtcttttctttggc cgctcaaacatggtgccccccctactgaagtcaataggggtctg rs885004 tcatgacCTTATGCAGTAAACATTCATTCTTCTAGCTTTTAAAA (at position TAATAGTGATTTTACCTATAGATTTTCAAATTACTAAAAAGTGA SLC28A3 201) AIG CTGCATTTTGGAAGCTACTTTAGTTCTGTG GACAGAGTACAGGAATAACATGATTGTTATTGGCCTGTACTTCA 3 TCAACTGCCAGAGCCTCCTGCAGGACAGGGACACCCTGAACTTC TTTAAGGAGAGCAAGTTTGATGCTCTTTTCACAGACCCAGCCTT ACCCTGTGGGGTGATCCTGGCTGAGTATTTGGGCCTACCATCTG TGTACCTCTTCAGGGGTTTTCCGTGTTCCCTGGAGCATACATTC AGCAGAAGCCCAGACCCTGTGTCCTACATTCCCAGGTGCTACAC AAAGTTTTCAGACCACATGACTTTTTCCCAACGAGT K GCCAACTTCCTTGTTAATTTGTTGGAGCCCTATCTATTTTATTG TCTGTTTTCAAAGTATGAAGAACTCGCATCAGCTGTCCTCAAGA GAGATGTGGATATAATCACCTTATATCAGAAGGTCTCTGTTTGG CTGTTAAGATATGACTTTGTGCTTGAATATCCTAGGCCGGTCAT GCCCAACATGGTCTTCATTGGAGGTATCAACTGTAAGAAGAGGA AAGACTTGTCTCAGGTTGGTGGGTTTATTTCTTTTGGACTGCCT TGTTTCTTCCAGGCTCTGTCCTCCCTCACTCATTTG TA/C* or (TAACAAGGAA GTTGGC rs17863783 G/T m (at position (forward ACTCGTTGGG AAAAAG) UGT1A6 301) strand) 23 WO 2012/162812 PCT/CA2012/000529 actccagcctgggcaacaaaagcaaaactccgtctcaaaaaaaa 4 aaCCCCCATatattatactacatattataataatttaatagtat tacaatatactttaattatatttaatatttatatgtttaacata taataacataatgcaatataatataatacaTAAAATGTCTGATG GGATAAATTTACATTGGGGGGAGAGGGCTGGAGATAGAGTTAGA GGTGGGTGTGGGGCTGCAATTATAAATAAGGAGGTCAAGGGGGC CCCCAGtgagtaaaaacccgggaggtgatggtgggagccacaga ggtttctagaggaagagcatttcaggcaagagggaaaagcaggt gcaaaggccctgaggtgggtgtatctgaggtgcaagagggaggt cggtgtggccggagccaagtgagcaagtggggaaaggagtggag atgaggtccgggtggggaggcaacaggggccaaaatgtgcaggg ccgcgtgggcccggtg M ggacttgagctctgaccgagtgacgaggcagcgcggcagggatc gcagcagaggaggagcccgagcgggcttaggcttcaccggcgcc ctctggcggtcagatggggaccgactgtcgagagagcagaagcc gggaagcccgagaggcggcgctggccggggtccaggggagggga cggtggctggactagggtgatggtcacggaggtattttgaaggt gagaccgggaggatttgctgacagactggatgtgggtgtgagag aaggggatgagtcaagggtgactccaaggtttcggcggaagcaa ctgtcagggtggggcaactgggaaggggaggagggaggggagca ggcgggggaggaagaCACGGGCTCTGCGGCGGCCCATCCCACGT rs10426377 CCAGCAGAGGCTGCCGGTGGGCACAGAAATGCACCCATCGGGAT (at position CTGAGGGGAGAGACTTGGGCTGACACGTCCATTTGCAATTCCTT SULT2B1 501) A/C GGCACATATATTCTGT AGGGAGCTATTGCAGCGGGACTAGTAAGGGCTGGCTTCCTGGCA 5 GAGGTGGCCTGTGAGGGGCCCTGAAGGAGGAGCGCCTGAGAGGA TCATTTGAGCCTAAGCCTTCCTGGAAACTGCTCTTTCTGGGCCC AGAGTCTCTGCAGCACATCAGGGACTAAGGTCTCAGCAGGAGCT GTCCCCATGACCCCTACCCCCACTTCTTGTCCTCAGCTACTCAG TAATTCTATAATTTGGAGGTTCATCTCTAA R AAAAAAACATACAGAAATATCTTACTTTTGCAAATTTTACAAAA TATAGCAAAAACATCTCATGAGGTGAACATTGCTGGGCTCCTCC CGGGCCCCAGGCTTAAGGTTCACTAACTTCCCAGTACGGCGACC rs2305364 TCTGCCCACAGGACTCCTCCCCTCCACCTGGGCCCCCACCATGC (at position CCAGACTCCCCTCTAGCTGGAGTCGCTGGGCGGTGGCTGCTAAA SLC28A1 251) AJG GGCCTCTGGGACCCTGAGTCAAGCTGACCT 24 WO 2012/162812 PCT/CA2012/000529 TTCTctgaagccttcatcttcatgataaaacctaggtctccaaa 6 accccttatcttaacccaaacattcctttctactgataattact ctttcaaccaattgccaatcagaatatgtttaaatctaactacg gcctggaagcccctggccctgcctttgagttgtcccggctcttc cagatccaaccattgtaaatcctgcacgtactgattgatgtatt acatctccctaaaatgtacaaagcaagctgtacttcgaccactt tgggcacgtgtcctcaggacctcctgaggctgtatcatgggtgc atccttaaccttggcaaaataaactttctaaattgattgagact tgtctcagataatttttggtttacaCAGCTTACACCTAGTGGGG GTAGTTTAAGAGACACTTAGGATACATTACCTTGTTTAATCCTC ATAGCAAGTCTTAAAGGAAGTTGGAAGCTAAGAGATTTGCCCAA AGTGGTAAAGCCAAAC y AGATGTGGTTTAAGAGGGAGGCCCTGGCACTGAGGTAGAAGTCT CAGTTTTCTGCTGCCACCTTCCAGAGAGCCAAGAGAACCCACTC TTGCCTTCCAAGGAATGTGCCCAAAAGTTAGAAGAGTTGGGAAG A/G*or TGACTACAGTATGCATCCATGAAGAGctctctgggatctaatc atgtctcagctttgccactcattagctttgtaaccttgggccag rs4982753 C/T ttactgagtctctctgaccataagttttctcatcttgtttaaga (at position (forward gaataagaatGCTGTACTGAGCTTCCATTGTTTTTTTCTGAGTG SLC22A17 501) strand) ACACCCAGTCCCGCTTCTGCTAACAGTGCCCAAATTTTG GGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCC 7 CACTGGCGGCCTTGCTGGATGGATGTGGCTGTCACTGCCCAAG CTTACTTATGGGGGGATCGCCCTGCTGGCTGCCGGCACCGCCCT CCTGCTGCCAGAGACGAGGCAGGCACAGCTGCCAGAGACCATCC AGGACGTGGAGAGAAAGAGGTGTGTGCACAGGACTGTGTCTGTG TACGTGTGATAACATGCATATGGATGCAGGTGCTCAGATACCTG ACACCTTAGGATTCAGACAGGAAACTATATCTGCACATGTGTAC TTGGTGCATGTATGTGTGCGTGCACAGGTGAGTGTTTCAGGGTG CATGATTGGGGGCATGTAAACTGCAAGCATAAATGTGTACATGA GTGT R TGAACACAAATACATAAGGTTGTTCAGGAAGATGTGTATGTGTG CACACTCAAGTATGCCTACACATCAGGGGTGTGTACAAGCATGT GTGTGAGTCACTTGTACAGGCGTTTGTATACCAGGAACTGGGGT GAGCCCTGGGACAGCCCTGATGGGGCAGGCTGGGGTGGTAGGCT CGGGGATTAAACCCCACCATTGCTCACAACTCCTTCCTCCCTAG TGCCCCAACCAGTCTTCAGGAGGAAGAGATGCCCATGAAGCAGG TCCAGAACTAAGTGGGAGTGGAGGCAGGCCCTCCACAGAAGCTC rs4149178 TGCAGCAGGGGCTGGGAGAGCAGAAGGGCAGGCCCTGCAACTCA (at position GGCTGGGAGTATCGAACCCTCTGCCTAGGGCCGGAGTTGCTGCC SLC22A7 401) G/A AGTA TTACCTAGTACTTAATTCCCTTATCCTCAACTCATTTATTCCTC 8 GCAATAACCTGATAAGGGAGATGTTTTTATCCTCATTTTACATA TAAGGAAACAGGCCTAGAGAAATGAGCACAGTGTCCAAAGTCAC ATAGTTAATAAGATGTGAAGCTCTGAGTTTGAAAGTCTCCGGTT TCAAAGCCATGAAACTTATGGCTCCCYGTTTTAGACACTTCCTT TTGGGAAGAGTGTGGAGGAATTAATCAGAAAGAAGAAAGTCATA CTCAAATAGGTGGTAGGAGYAGAGACAATTCAATAC R GACAGAAGTCTTAGATGAGAGCAGTGAGCCAGGGCACTGGACTG GGACTCAGGAGGCTTCCCCTAGACTCTGGTTCCACMGATGCAGC CTCAGGCAGGACTTCACCTCTCTGGGCATCCGTTTCTTCATATG TTAAACATACGGGGTTTTAATTAGATGATCGCTGAAGACCCCTC rs4148808 TAGCCCTAAAACTCTGTGTCTCTTAAGTGCTAAGAGGGCACCAA (at position CAGCGTTCCTCCTCCCCAAGGAGCATAATGTGATGGTTCCTGCC ABCB4 301) A/G GGCCCTGGCTGACTCTCGCCGTCCTTGGAGATAATT 25 WO 2012/162812 PCT/CA2012/000529 AGCACTTTTCTCACGACTTGGATCAATGAAAAAGGAAATTGCTT 9 AGATTAAATGATCAAATTTCACTTAGCTACCTTGCAATATTTGA ATGCAGTGACTTACTTTTTTACGTCAAAACTTTTTCTTTTTCAC TGTAGTCAGTTTATTTAATGTAGTTTATTTAAAATCATACCAAA CATGCAGTGATAAT T T T T TGGAGA K GGGGAACCACAGCAAAATATACTGTCAATTTTGGTCCCACCGAT AATTTATCTACCCCCCATCCCATATAGAAATCATAAGATTCTCA GT CTGGCTACAACATGAAAGTGAAAAAGATAAAAACTAGGAAGA GAAACGTCTTTGCTCTGCACTAGTGCAGATGTCCTTTTCCAAAA TGAGATCAGtattattatattatctaaagatacatttaaaaaat attaataaGAGGTATTTTCTTTCATTTATTACTAACAGGTCATT CATTTCATATAATTAAATGTCACTTTAGTCAGTACAACTTATTC AATGTAGTTGATTCAAAAAT (GGGGGGTAGATAAATTATCGGTGGGACCAAAATTGACAGTATA rsl 149222 C/A* or TTTTGCTGTGGTTCCCC (at position G/T M 201* AND (forward TCTCCAAAAAATTATCACTGCATGTTTGGTATGATTTTAAATAA ABCB4 61) strand) ACTACATTAAATAAAC) GCTTGACCTTCATCCATTTTATAGTCACTAGAAGATTTTAAGCA 10 GGGAAGTGATAGGTTTGCTTAGCAGGGTTTAAAATGGTTATCAT GGTAAGTGCTTTGAGGAATACAAGACCAGAGGTAGGCTGACCTT TTAGGATATTATTGCAGTATTCCAAATGTGAATAATCTTGACCT GAATAAGAGCACAGCTAGTAGGGACAGAATTGAGAAAGTAAACT TCTTGATGGCCAGGAAAGGAAGATAAAGGAAGAAGAAACTTTGA GTGATGATGGATAGCAAACAGCATGGGTGAATGTTT M AAGAAAAGATAATACTTTAAAACTAAATGTTAAATGGTTAAACA AGACTATAATATGACAGATCTGAACTATTGACCCCCCTTTTTTT AAACAGGCAAGAGGATTATATACATCTTTTTGTTGGCCGGACGT GGTTACTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGTA rs17583889 GGCAGATCACTTGAGGTCAAGAGTTCGAGACCAGCCTGGCCAAT (at position ATGGTGAAACCCCGTCTCTACTAAAAATATGAAAATTAGCCTGG HNMT 301) A/C CATGGTGGTACGTGTCTGTAATCCCAGCTACTTGGG CTCCTTCCCAAAAGCGAATTATTGTCATGTGTTTTTGTGTGTGT 11 GTGTTTTAATTGAATATAGGAAGCTCCAGCCGAGCGCCTCTTGA GCAATGTGAAAGAGTACTCAATGTGATTCATATTGACTTCCCAG GCTAGTGGGTTAAGGAGAAACAATATTCTTCTTCCCTACATAAC ATAGTTACTTCCTACCTTAGAACTTTTGTATTCAAAGTACGTGC TTGACAAGAAGTCTACACCTGTACTCCAGCAGGTTTGGATCCCT GATGGACTTACACTTACATGATCTCCCAAATTGTAA M CTCCATTTAACAAACTCTCCAAACCTGCTTGACTGGCTTACTCA TGGAGTAACTCAGCCTTTCCTGTGTGTTTGTGCAGAGTGAGGCC CATTTCCCCAGCCTAGTCCTCTCCCAAGACTTTCGTAAGTGAGT TCCACCCAACTAACTTCAGAGCAAGCTTGGGTTCTGTGCCTCTG rs4877847 AGAGCAGCTGTGGCAAGATTGATTGCTTATTCACAGGGAGGAGG (at position AAACTTGAGTTGGGATTCCAAGAGATGCCTTTTAATAAATGTGT SLC28A3 301) A/C TAAAAAACATTCCTGCATTTTCCTCTTAGAAATTCT 26 WO 2012/162812 PCT/CA2012/000529 SLC22A17 rs11625724 TGGGAAGGTGACTACAGTATGCATCCATGAAGAGCTCTCTGGGA 12 (at position TCTAATCATGTCTCAGCTTTGCCACTCATTAGCTTTGTAACCTT 301) GGGCCAGTTACTGAGTCTCTCTGACCATAAGTTTTCTCATCTTG TTTAAGAGAATAAGAATGCTGTACTGAGCTTCCATTGTTTTTTT CTGAGTGACACCCAGTCCCGCTTCTGCTAACAGTGCCCAAATTT TGCTTTACCTATTCCCAGTTGGGAGAAATAGGGGTGTGGGAGGC ATGTTACTCTAGCTAGCCAGTGACATGCTCTCTGGA w ATTAATCTTCAGTGGGATAACCCAAAGATTAAATTGCACTGGAG CT CAT TCAT CTAGAAGAAGCCCTGACAAAAATGT TGCTGGT T T T TGCTCCTCAGACAAGGAGCCTTCTCCGCTCCTGACTAGTTATTT TACGACGAGTTCTGCTTCTCCTTCATTCTGTGAGCTCCCACCAC AACCTGCCCCACCAAATCGAATAATTCCCTTTTTGCTTAAGTTC ATTAGAGCCAGTTTTTATTGCTTACAACAACACAACAACAACAA A/T CAACAACAACAACCCCTAATTGATCCAAACACCTAC SLC22A17 rs12882406 AAGCTGGAGTGCCAGTCAAACAAATGCGCCACTTTATAGCCCTT 13 (at position TGTGGAGCATTTATTCGTGCTGATGGCAAAAGACTGTGGGCACT 501) TCCCAATGACAGTGACTGGGCTAGAGAATTTCCACTTGAGGGGC ATTTACTGCCTTGCTGTGGAATGTTGACAGAAGCTATCTTATGC CAATGGAAATAATGGTGCCCAAAGGAGCACCATGACAAAATAAA AATGGTTTACATAAGATCTTGCTACCTGAGGATACAAGGAGGAG ATCCTTATGAGCAGGAAGCCTCTTTTTTTAAAATTTTTTTCCCT AGGACTGATTCTAACTATGTGAGGAGCTACTAGATTCTACAGTG CCTGATAGACAACTCTCATTAGCTGTTTGGCTTGTGAATGGCAG TTCCAAGGTGAACAAACATCCTGTTTGAAAGCCCCTGTTCTGGC TATAGAAGTGTCAAACAAATCCTTTTCTTTTGAGTTATTCACAG TTTAAAGCAACTGGGT S AAGTATGTGTTTGTAAGCAAATTTGCCTTTCTATCTATCTGAGT TCTCCAAAATTTGGATTGTGAGTTCATGACAATACAGTCATTTG CATAAGCTTAGTAAGAGTCTTTTAGAACAGAGCAATTGGAGACG CTGGTTATTTTGCCAAGGCTTTGACTAGAATAACATATTTGTAG GTAAAGTTCCAGCAAAGCCAACTTAATAGAAGCCTATATGGCCA AACAATTCTTGCTGCACTTTATATGAATAATCAGGCAAAGTATA ATAAGCCTAAAATTTATTTTGTACACAAATTTCAGCCCTGGCTT TTGTTTTTGAGTGCAGATCGAAGAACGAATTATTTCTTGGCTAC AATAATCCTCTGAAGAGTATCACATTATAATTTTTCTTCATATG TTTAGTCGGTACTCTAATAGAATAGCTCCCTTTTTCTGTTCTGA CATACAAATATTCTTTTGATTGTCAAAATATTTATGTTATTTAT C/G CTGTCCTTGTTTTATT SLC22A17 rs12896494 ACTGTGGGGAAGATAGGATGCTCACAATCCCACAGGCCCAGCAG 14 (at position GACCAGGGAAGCAATGCCGGTAAGGGTCATGGAGAGAAGAAGGA 301) TGCCCCGGCGGCCAAATCGGTCCACGGTGACCCCCAGGAAGACA CAGGCCAGGGCTGCGGTGCCGCTGGCCAGCAGAGAGCACAGGTA GAAGTCCGATGGGCTCCCTCCTCCTCCCACAGGCTGGTAGCAGT GGCGAATGGCATGGGCAATGAAGCTGTGAGAAGGGGTGGGGAAG CAACGAACAGAGCCTGAATCCCCTCCCGCAGCCTTC y ACAGTGCTGATGGTCCTCCGCAGGGGTCCCCGGGCCTTCCCACC CAGCCAGCCCCCATTCCAGCTACTGGCCTGGCCCTCAGCCCAGA CACCCAGGCTCACTTGGTGAAGCCCAGGATAAGCAGATTTTTCC AGATGTTGCGGTAGTTGAGGAGGGAAGCAAAGGAAAAGGAGGAT GTTGCAGGGAGAGGGCAGGTATTCTCCAGGTCTTTGGGAGAGAG AGAGGAGCTGTCAGAAGAAAACCCTGAGATCCCAGGATCCTCCC CIT ACATGGGTGGTGGGGACCCTGGGAGAAGGTGGCACA 27 WO 2012/162812 PCT/CA2012/000529 SULT2B1 rs10426628 GAGAGGGCTGGAGATAGAGTTAGAGGTGGGTGTGGGGCTGCAAT 15 (at position TATAAATAAGGAGGTCAAGGGGGCCCCCAGTGAGTAAAAACCCG 501) GGAGGTGATGGTGGGAGCCACAGAGGTTTCTAGAGGAAGAGCAT TTCAGGCAAGAGGGAAAAGCAGGTGCAAAGGCCCTGAGGTGGGT GTATCTGAGGTGCAAGAGGGAGGTCGGTGTGGCCGGAGCCAAGT GAGCAAGTGGGGAAAGGAGTGGAGATGAGGTCCGGGTGGGGAGG CAACAGGGGCCAAAATGTGCAGGGCCGCGTGGGCCCGGTGCGGA CTTGAGCTCTGACCGAGTGACGAGGCAGCGCGGCAGGGATCGCA GCAGAGGAGGAGCCCGAGCGGGCTTAGGCTTCACCGGCGCCCTC TGGCGGTCAGATGGGGACCGACTGTCGAGAGAGCAGAAGCCGGG AAGCCCGAGAGGCGGCGCTGGCCGGGGTCCAGGGGAGGGGACGG TGGCTGGACTAGGGTG N TGGTCACGGAGGTATTTTGAAGGTGAGACCGGGAGGATTTGCTG ACAGACTGGATGTGGGTGTGAGAGAAGGGGATGAGTCAAGGGTG ACTCCAAGGTTTCGGCGGAAGCAACTGTCAGGGTGGGGCAACTG GGAAGGGGAGGAGGGAGGGGAGCAGGCGGGGGAGGAAGACACGG GCTCTGCGGCGGCCCATCCCACGTCCAGCAGAGGCTGCCGGTGG GCACAGAAATGCACCCATCGGGATCTGAGGGGAGAGACTTGGGC TGACACGTCCATTTGCAATTCCTTGGCACATATATTCTGTAATT AATCGAAGCTCCAGGACTGGGTGATATCGCCAAGGAATTGAGCG TGGACAGAGCAGAGAGGGGGGGCTGCAATCAGGAAGTCCCCAAG ACCACCCTCAGGCTCAACGACTTAGCAAAACTCATAGTGTTCAG CAAAGCTGCTGGACTCCCGGGTTATAGTCAATTACAATGAAAGC A/C/G/T AAACGTGAAAATCAGG It will be appreciated by a person of skill in the art that further linked polymorphic sites and combined polymorphic sites may be determined. A haplotype of the above genes can be created by assessing polymorphisms in normal subjects using a program that has an expectation maximization algorithm (for example PHASE). A constructed haplotype of these genes may be used to find combinations of SNPs that are in LD with the tag SNPs (tSNPs) identified herein. Accordingly, the haplotype of an individual could be determined by genotyping other SNPs or other polymorphisms that are in LD with the tSNPs identified herein. Single polymorphic sites or combined polymorphic sites in LD may also be genotyped for assessing subject risk of cardiotoxicity following anthracycline treatment. It will be appreciated by a person of skill in the art that the numerical designations of the positions of polymorphisms within a sequence are relative to the specific sequence and the orientation of the strand being read (i.e. forward or reverse). Also the same positions may be assigned different numerical designations depending on the way in which the sequence is numbered and the sequence chosen. Furthermore, sequence variations within the population, such as insertions or deletions, may change the relative position and subsequently the numerical designations of particular nucleotides at and around a polymorphic site. For example, the sequences represented by accession numbers NC_000014.8, NM_016609, AJ243653.1 and BCl 11015.1 all comprise SLC22A17 nucleotide sequences, but may have some sequence differences and numbering differences between them. Furthermore, one of skill in the art 28 WO 2012/162812 PCT/CA2012/000529 will appreciate that a variety of sequencing, amplification, extension, genotyping or hybridization primers or probes may be designed to specifically identify the polymorphisms described in TABLE 2, and the sequences flanking the various polymorphisms as provided herein are illustrative examples. One of skill in the art will also appreciate that a variety of sequencing, amplification, extension, genotyping or hybridization primers or probes adjacent to, complimentary to, or overlapping with the sequences provided in TABLE 2, may be developed or designed for the identification of the polymorphisms described herein, without going beyond the scope of various embodiments described herein. The gene sequences described herein in association with SLC28A3, SLC28A3, UGT1A6, SULT2B1, SLC28Al, SLC22AI 7, SLC22A7, ABCB4, ABCB4, and HNMT are meant to include genomic sequences, cDNA sequences, mRNA sequences, and further may include 5' and 3' untranslated sequences, introns and the like. Sequence databases with this information, such as GenBank, operated by the National Centre for Biotechnology Information (NCBI) store such information in a retrievable format, and are publicly accessible. A person of skill in the art will appreciate the various methods and tools that may be used to access such information, in a context suitable to their particular application of aspects described herein. Furthermore, a person of skill in the art would appreciate that the sequences may appear in either orientation (either forward or reverse strand or both). Polymorphic sites in SEQ ID NO: 1-15 are identified by their variant designation (i.e. M, W, Y, S, R, K, V, B, D, H, N or by "-" for a deletion, a "+"or for example "G" etc. for an insertion). An "rs" prefix designates a SNP in the database is found at the NCBI SNP database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Snp). The "rs" numbers are the NCBI | rsSNP ID form. The Sequences given in TABLE 2 (SEQ ID NO:1-15) above may be useful to a person of skill in the art in the design of primers and probes or other oligonucleotides or PNAs for the identification of polymorphisms as described herein. An "allele" is defined as any one or more alternative forms of a given gene. In a diploid cell or organism the members of an allelic pair (i.e. the two alleles of a given gene) occupy corresponding positions (loci) on a pair of homologous chromosomes and if these alleles are genetically identical the cell or organism is said to be "homozygous", but if genetically different the cell or organism is said to be "heterozygous" with respect to the particular gene. 29 WO 2012/162812 PCT/CA2012/000529 A "gene" is an ordered sequence of nucleotides located in a particular position on a particular chromosome that encodes a specific functional product and may include untranslated and untranscribed sequences in proximity to the coding regions (5' and 3' to the coding sequence). Such non-coding sequences may contain regulatory sequences needed for transcription and translation of the sequence or introns etc. or may as yet to have any function attributed to them beyond the occurrence of the SNP of interest. A "genotype" is defined as the genetic constitution of an organism, usually in respect to one gene or a few genes or a region of a gene relevant to a particular context (i.e. the genetic loci responsible for a particular phenotype). A "phenotype" is defined as the observable characters of an organism. In gene association studies, the genetic model at a given locus can change depending on the selection pressures (i.e., the environment), the population studied, or the outcome variable (i.e., the phenotype). A similar observation would be seen in a gene association study with the hemoblobin, beta gene (HBB) with mortality as the primary outcome variable. A mutation in the HBB gene, which normally produces the beta chain subunit of hemoglobin (B allele), results in an abnormal beta chain called hemoglobin S (S allele; Allison A (1955) Cold Spring Harbor Symp. Quant. Biol. 20:239-255). Hemoglobin S results in abnormal sickle-shaped red blood cells which lead to anemia and other serious complications including death. In the absence of malaria, a gene association study with the HBB gene would suggest a codominant model (survival(BB) > survival (BS) > survival (SS)). However, in the presence of marlaria, a gene association study with the HBB gene would suggest a heterozygote advantage model (survival(BB) < survival(BS) > survival(SS)). A "single nucleotide polymorphism" (SNP) occurs at a polymorphic site occupied by a single nucleotide, which is the site of variation between allelic sequences. The site is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). A single nucleotide polymorphism usually arises due to substitution of one nucleotide for another at the polymorphic site. A "transition" is the replacement of one purine by another purine or one pyrimidine by another pyrimidine. A "transversion" is the replacement of a purine by a pyrimidine or vice versa. Single nucleotide polymorphisms can also arise from a deletion (represented by -" or "del") of a nucleotide or an insertion (represented by "+" or "ins" or "I") of a nucleotide relative to 30 WO 2012/162812 PCT/CA2012/000529 a reference allele. Furthermore, a person of skill in the art would appreciate that an insertion or deletion within a given sequence could alter the relative position and therefore the position number of another polymorphism within the sequence. Furthermore, although an insertion or deletion may by some definitions not qualify as a SNP as it may involve the deletion of or insertion of more than a single nucleotide at a given position, as used herein such polymorphisms are also called SNPs as they generally result from an insertion or deletion at a single site within a given sequence. A "subject", as used herein, refers to a patient or test subject, for example a human patient. The subject may have been previously diagnosed with a neoplastic disorder, or may be suspected of having a neoplastic disorder and thus may be a candiate for a chemotherapeutic regimen. The subject may be selected as part of a general population (for example a 'control' subject), or may be selected as part of a particular ethnic, gender, age or genetic subgroup of a population, or may be excluded from selection as part of a particular ethnic, gender, age or genetic subgroup of a population. Patients and test subjects, whether control or not, may be generally referred to as a subject. As used herein, the terms "cancer" or "neoplastic condition" or "neoplastic disorder" or "neoplastic disease" refer to a proliferative disorder caused or characterized by the proliferation of cells which have lost susceptibility to normal growth control. A "cancer" or "neoplastic condition" or "neoplastic disorder" or "neoplastic disease" may include tumors and any other proliferative disorders. Cancers of the same tissue type usually originate in the same tissue, and may be divided into different subtypes based on their biological characteristics. Four general categories of cancers are carcinoma (epithelial tissue derived), sarcoma (connective tissue or mesodermal derived), leukemia (blood-forming tissue derived) and lymphoma (lymph tissue derived). Over 200 different types of cancers are known, and every organ and tissue of the body may be affected. Specific examples of cancers that do not limit the definition of cancer may include melanoma, leukemia, astrocytoma, glioblastoma, retinoblastoma, lymphoma, glioma, Hodgkins' lymphoma and chronic lymphocyte leukemia. Examples of organs and tissues that may be affected by various cancers include pancreas, breast, thyroid, ovary, uterus, testis, prostate, thyroid, pituitary gland, adrenal gland, kidney, stomach, esophagus or rectum, head and neck, bone, nervous system, skin, blood, nasopharyngeal tissue, lung, urinary tract, cervix, vagina, exocrine glands and endocrine glands. Alternatively, a cancer may be multicentric or of unknown primary site (CUPS). As used herein, a "therapeutic regimen" refers to a chemotherapeutic regimen or a radiotherapy regimen, or a combination thereof. 31 WO 2012/162812 PCT/CA2012/000529 As used herein, a "chemotherapeutic regimen" or "chemotherapy" refers to the use of at least one chemotherapy agent to destroy cancerous cells. There are a myriad of such chemotherapy agents available for treating cancer. Chemotherapy agents may be administered to a subject in a single bolus dose, or may be administered in smaller doses over time. A single chemotherapeutic agent may be used (single-agent therapy) or more than one agent may be used in combination (combination therapy). Chemotherapy may be used alone to treat some types of cancer. Alternatively, chemotherapy may be used in combination with other types of treatment, for example, radiotherapy or alternative therapies (for example immunotherapy) as described herein. Additionally, a chemosensitizer may be administered as a combination therapy with a chemotherapy agent. As used herein, a "chemotherapeutic agent" or "chemotherapeutic agent" refers to a medicament that may be used to treat cancer, and generally has the ability to kill cancerous cells directly. Examples of chemotherapeutic agents include alkylating agents, antimetabolites, natural products, hormones and antagonists, and miscellaneous agents. Examples of alternate names are indicated in brackets. Examples of alkylating agents include nitrogen mustards such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan (L-sarcolysin) and chlorambucil; ethylenimines and methylmelamines such as hexamethylmelamine and thiotepa; alkyl sulfonates such as busulfan; nitrosoureas such as carmustine (BCNU), semustine (methyl-CCNU), lomustine (CCNU) and streptozocin (streptozotocin); DNA synthesis antagonists such as estramustine phosphate; and triazines such as dacarbazine (DTIC, dimethyl triazenoimidazolecarboxamide) and temozolomide . Examples of antimetabolites include folic acid analogs such as methotrexate (amethopterin); pyrimidine analogs such as fluorouracin (5-fluorouracil, 5 FU, 5FU), floxuridine (fluorodeoxyuridine, FUdR), cytarabine (cytosine arabinoside) and gemcitabine; purine analogs such as mercaptopurine (6-mercaptopurine, 6-MP), thioguanine (6-thioguanine, TG) and pentostatin (2'-deoxycoformycin, deoxycoformycin), cladribine and fludarabine; and topoisomerase inhibitors such as amsacrine. Examples of natural products include vinca alkaloids such as vinblastine (VLB) and vincristine; taxanes such as paclitaxel and docetaxel (Taxotere); epipodophyllotoxins such as etoposide and teniposide; camptothecins such as topotecan or irinotecan; antibiotics such as dactinomycin (actinomycin D), bleomycin, mitomycin (mitomycin C); anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), doxorubicin, idarubicin, epirubicin; enzymes such as L asparaginase; and biological response modifiers such as interferon alpha and interleukin 2. Examples of hormones and antagonists include luteinising releasing hormone agonists such as buserelin; adrenocorticosteroids such as prednisone and related preparations; progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogens such as diethylstilbestrol and ethinyl estradiol and related preparations; estrogen antagonists such as tamoxifen 32 WO 2012/162812 PCT/CA2012/000529 and anastrozole; androgens such as testosterone propionate and fluoxymesterone and related preparations; androgen antagonists such as flutamide and bicalutamide; and gonadotropin-releasing hormone analogs such as leuprolide. Examples of miscellaneous agents include thalidomide; platinum coordination complexes such as cisplatin (cis-DDP), carboplatin, oxaliplatin, tetraplatin, ormiplatin, iproplatin or satraplatin; anthracenediones such as mitoxantrone; substituted ureas such as hydroxyurea; methylhydrazine derivatives such as procarbazine (N-methylhydrazine, MIH); adrenocortical suppressants such as mitotane (o,p'-DDD) and aminoglutethimide; RXR agonists such as bexarotene; or tyrosine kinase inhibitors such as imatinib. Alternate names and trade-names of these and additional examples of chemotherapeutic agents, and their methods of use including dosing and administration regimens, will be known to an individual versed in the art, and may be found in, for example "The Pharmacological basis of therapeutics", 10th edition. HARDMAN HG., LIMBIRD LE. editors. McGraw Hill, New York, or in "Clinical Oncology", 3rd edition. Churchill Livingstone/ Elsevier Press, 2004. ABELOFF, MD. editor. 2. General Methods Once a subject is identified as a candidate for anthracycline administration, then genetic sequence information may be obtained from the subject to determine the risk of cardiotoxicity for the subject. Genetic sequence information may be obtained from a subject by any of several methods. For example, a biological sample comprising genetic material with a sequence or sequences of interest, may be obtained from the subject, for example a blood sample, a saliva sample, a hair sample including a follicle, skin scraping, such as a cheek scraping and the like. Or alternatively genetic sequence information may already have been obtained from the subject. For example, a subject may have already provided a biological sample for other purposes or may have even had their genetic sequence determined in whole or in part and stored for future use. Genetic sequence information may be obtained in numerous different ways and may involve the collection of a biological sample that contains genetic material, particularly, genetic material containing the sequence or sequences of interest. Many methods are known in the art for collecting biological samples and extracting genetic material from those samples. Genetic material can be extracted from blood, tissue, hair and other biological material. There are many methods known to isolate DNA and RNA from biological material. Typically, DNA may be isolated from a biological sample when first the sample is lysed and then the DNA is separated from the lysate according to any one of a variety of multi-step protocols, which can take varying lengths of time. DNA isolation methods may involve the use of phenol (Sambrook, J. et al., "Molecular Cloning", Vol. 2, pp. 9.14-9.23, Cold Spring Harbor Laboratory Press (1989) and Ausubel, Frederick M. et al., "Current Protocols in Molecular Biology", Vol. 1, pp. 2.2.1-2.4.5, John Wiley & Sons, Inc. (1994)). Typically, a biological sample is 33 WO 2012/162812 PCT/CA2012/000529 lysed in a detergent solution and the protein component of the lysate is digested with proteinase for 12-18 hours. Next, the lysate is extracted with phenol to remove most of the cellular components, and the remaining aqueous phase is processed further to isolate DNA. In another method, described in Van Ness et al. (U.S. Pat. # 5,130,423), non-corrosive phenol derivatives are used for the isolation of nucleic acids. The resulting preparation is a mix of RNA and DNA. Other methods for DNA isolation utilize non-corrosive chaotropic agents. These methods, which are based on the use of guanidine salts, urea and sodium iodide, involve lysis of a biological sample in a chaotropic aqueous solution and subsequent precipitation of the crude DNA fraction with a lower alcohol. The resulting nucleic acid sample may be used 'as-is' in further analyses or may be purified further. Additional purification of the precipitated, crude DNA fraction may be achieved by any one of several methods, including, for example, column chromatography (Analects, (1994) Vol 22, No. 4, Pharmacia Biotech), or exposure of the crude DNA to a polyanion-containing protein as described in Koller (U.S. Pat. # 5,128,247). Yet another method of DNA isolation, which is described by Botwell, D. D. L. (Anal. Biochem. (1987) 162:463-465) involves lysing cells in 6M guanidine hydrochloride, precipitating DNA from the lysate at acid pH by adding 2.5 volumes of ethanol, and washing the DNA with ethanol. Numerous other methods are known in the art to isolate both RNA and DNA, such as the one described by CHOMCZYNSKI (U.S. Pat. # 5,945,515), whereby genetic material can be extracted efficiently in as little as twenty minutes. EVANS and HUGH (U.S. Pat. # 5,989,431) describe methods for isolating DNA using a hollow membrane filter. The level of expression of specific nucleic acids such as mRNAs or microRNAs, copy number of a gene, or the degree of heterozygosity for a polymorphism may also be determined once the nucleic acid sample has been obtained. Quantitative and semi-quantitative methods are known in the art, and may be found in, for example AUSUBEL, supra; SAMBROOK, supra or Harrison's Principles of Internal Medicine 15th ed. BRAUNWALD et al eds. McGraw-Hill. Once a subject's genetic material has been obtained from the subject it may then be further be amplified by Reverse Transcription Polymerase Chain Reaction (RT-PCR), Polymerase Chain Reaction (PCR), Transcription Mediated Amplification (TMA), Ligase chain reaction (LCR), Nucleic Acid Sequence Based Amplification (NASBA) or other methods known in the art, and then further analyzed to detect or 34 WO 2012/162812 PCT/CA2012/000529 determine the presence or absence of one or more polymorphisms or mutations in the sequence of interest, provided that the genetic material obtained contains the sequence of interest. Particularly, a person may be interested in determining the presence or absence of a polymorphism in a cardiotoxicity associated gene sequence, as described herein. Detection or determination of a nucleotide identity, or the presence of one or more single nucleotide polymorphism(s) (SNP typing), may be accomplished by any one of a number methods or assays known in the art. Many DNA typing methodologies are useful for use in the detection of SNPs. The majority of SNP genotyping reactions or assays can be assigned to one of four broad groups (sequence-specific hybridization, primer extension, oligonucleotide ligation and invasive cleavage). Furthermore, there are numerous methods for analyzing/detecting the products of each type of reaction (for example, fluorescence, luminescence, mass measurement, electrophoresis, etc.). Furthermore, reactions can occur in solution or on a solid support such as a glass slide, a chip, a bead, etc. In general, sequence-specific hybridization involves a hybridization probe, which is capable of distinguishing between two DNA targets differing at one nucleotide position by hybridization. Usually probes are designed with the polymorphic base in a central position in the probe sequence, whereby under optimized assay conditions only the perfectly matched probe target hybrids are stable and hybrids with a one base mismatch are unstable. A strategy which couples detection and sequence discrimination is the use of a "molecular beacon", whereby the hybridization probe (molecular beacon) has 3' and 5' reporter and quencher molecules and 3' and 5' sequences which are complementary such that absent an adequate binding target for the intervening sequence the probe will form a hairpin loop. The hairpin loop keeps the reporter and quencher in close proximity resulting in quenching of the fluorophor (reporter) which reduces fluorescence emissions. However, when the molecular beacon hybridizes to the target the fluorophor and the quencher are sufficiently separated to allow fluorescence to be emitted from the fluorophor. Similarly, primer extension reactions (i.e. mini sequencing, nucleotide-specific extensions, or simple PCR amplification) are useful in sequence discrimination reactions. For example, in mini sequencing a primer anneals to its target DNA immediately upstream of the SNP and is extended with a single nucleotide complementary to the polymorphic site. Where the nucleotide is not complementary, no extension occurs. 35 WO 2012/162812 PCT/CA2012/000529 Oligonucleotide ligation assays require two sequence-specific probes and one common ligation probe per SNP. The common ligation probe hybridizes adjacent to a sequence-specific probe and when there is a perfect match of the appropriate sequence-specific probe, the ligase joins both the sequence-specific and the common probes. Where there is not a perfect match the ligase is unable to join the sequence-specific and common probes. Probes used in hybridization can include double-stranded DNA, single-stranded DNA and RNA oligonucleotides, and peptide nucleic acids. Hybridization methods for the identification of single nucleotide polymorphisms or other mutations involving a few nucleotides are described in the U.S. Pat. 6,270,961; 6,025,136; and 6,872,530. Suitable hybridization probes for use in accordance with the invention include oligonucleotides and PNAs from about 10 to about 400 nucleotides, alternatively from about 20 to about 200 nucleotides, or from about 30 to about 100 nucleotides in length. A unimolecular segment amplification method for amplifying nucleic acids is described in US patent 5854033. A rolling circle replication reporter system may be used for identification of polymorphisms or mutations. An invasive cleavage method employs an "InvaderTM" (Applied Biosystems) probe and sequence-specific probes to hybridize with the target nucleic acid, usually DNA, with an overlap of one nucleotide. When the sequence specific probe is an exact match to the site of polymorphism, the overlapping probes form a structure that is specifically cleaved by a FLAP endonuclease, Release of the 5' end of the allele-specific probe may be detected by known methods as described. See for example, Lu, M., et al. J. Am. Chem. Soc. 2001, 124, 7924 - 7931; Lyamichev, et al. 1999. Nature Biotech. 17, 292 - 296; Landegren et al. 1998. Genome Research, 8, 769 - 776; Brookes, 1999. Gene 234, 177 - 186; Chen, et al 2004. J. Am. Chem. Soc. 126, 3016-3017; Wang, D.G., et al. Science 1998, 280, 1077 - 1082. The TaqManTM assay (Applied Biosystems) exploits the 5' exonuclease activity of the Taq polymerase to displace and cleave an oligonucleotide probe hybridized to the target nucleic acid, usually DNA, generating a fluorescent signal. See, for example U.S. Patents 4,683,202, 4,683,195, and 4,965,188. 5' exonuclease activity or TaqManTM assay (Applied BiosystemsTM) is based on the 5' nuclease activity of Taq polymerase that displaces and cleaves the oligonucleotide probes hybridized to the target DNA generating a fluorescent signal. It is necessary to have two probes that differ at the polymorphic site wherein one probe is complementary to the 'normal' sequence and the other to the mutation of interest. These probes have different fluorescent dyes attached to the 5' end and a quencher attached to the 3' end when the probes are intact the quencher interacts with the fluorophor by fluorescence resonance energy transfer (FRET) to quench the fluorescence of the probe. During the PCR annealing step the 36 WO 2012/162812 PCT/CA2012/000529 hybridization probes hybridize to target DNA. In the extension step the 5' fluorescent dye is cleaved by the 5' nuclease activity of Taq polymerase, leading to an increase in fluorescence of the reporter dye. Mismatched probes are displaced without fragmentation. The presence of a mutation in a sample is determined by measuring the signal intensity of the two different dyes. The Illumina Golden GateTM Assay uses a combined oligonucleotide ligation assay/ allele-specific hybridization approach (SHEN R et al Mutat Res 2005573:70-82). The first series of steps involve the hybridization of three oligonucleotides to a set of specific target SNPs; two of these are fluorescently labelled allele-specific oligonucleotides (ASOs) and the third a locus-specific oligonucleotide (LSO) binding 1-20 bp downstream of the ASOs. A second series of steps involve the use of a stringent polymerase with high 3' specificity that extends only oligonucleotides specifically matching an allele at a target SNP. The polymerase extends until it reaches the LSO. Locus-specificity is ensured by requiring the hybridization of both the ASO and LSO in order that extension can proceed. After PCR amplification with universal primers, these allele-specific oligonucleotide extension products are hybridized to an array which has multiple discretely tagged addresses (in this case 1536 addresses) which match an address embedded in each LSO. Fluorescent signals produced by each hybridization product are detected by a bead array reader from which genotypes at each SNP locus may be ascertained. It will be appreciated that numerous other methods for sequence discrimination and detection are known in the art and some of which are described in further detail below. It will also be appreciated that reactions such as arrayed primer extension mini sequencing, tag microarrays and sequence-specific extension could be performed on a microarray. One such array based genotyping platform is the microsphere based tag-it high throughput genotyping array (BORTOLIN S. et al. Clinical Chemistry (2004) 50(11): 2028-36). This method amplifies genomic DNA by PCR followed by sequence-specific primer extension with universally tagged genotyping primers. The products are then sorted on a Tag-It array and detected using the Luminex xMAP system. Mutation detection methods may include but are not limited to the following: Restriction Fragment Length Polymorphism (RFLP) strategy - An RFLP gel-based analysis can be used to indicate the presence or absence of a specific mutation at polymorphic sites within a gene. Briefly, a short segment of DNA (typically several hundred base pairs) is amplified by PCR. Where possible, a specific restriction endonuclease is chosen that cuts the short DNA segment when one polymorphism is present but does not cut the short DNA segment when the polymorphism is not present, or vice versa. After incubation of the PCR amplified DNA with this restriction endonuclease, the reaction products are 37 WO 2012/162812 PCT/CA2012/000529 then separated using gel electrophoresis. Thus, when the gel is examined the appearance of two lower molecular weight bands (lower molecular weight molecules travel farther down the gel during electrophoresis) indicates that the DNA sample had a polymorphism was present that permitted cleavage by the specific restriction endonuclease. In contrast, if only one higher molecular weight band is observed (at the molecular weight of the PCR product) then the initial DNA sample had the polymorphism that could not be cleaved by the chosen restriction endonuclease. Finally, if both the higher molecular weight band and the two lower molecular weight bands are visible then the DNA sample contained both polymorphisms, and therefore the DNA sample, and by extension the subject providing the DNA sample, was heterozygous for this polymorphism; For example the Maxam-Gilbert technique for sequencing (MAXAM AM. and GILBERT W. Proc. Natl. Acad. Sci. USA (1977) 74(4):560-564) involves the specific chemical cleavage of terminally labelled DNA. In this technique four samples of the same labeled DNA are each subjected to a different chemical reaction to effect preferential cleavage of the DNA molecule at one or two nucleotides of a specific base identity. The conditions are adjusted to obtain only partial cleavage, DNA fragments are thus generated in each sample whose lengths are dependent upon the position within the DNA base sequence of the nucleotide(s) which are subject to such cleavage. After partial cleavage is performed, each sample contains DNA fragments of different lengths, each of which ends with the same one or two of the four nucleotides. In particular, in one sample each fragment ends with a C, in another sample each fragment ends with a C or a T, in a third sample each ends with a G, and in a fourth sample each ends with an A or a G. When the products of these four reactions are resolved by size, by electrophoresis on a polyacrylamide gel, the DNA sequence can be read from the pattern of radioactive bands. This technique permits the sequencing of at least 100 bases from the point of labeling. Another method is the dideoxy method of sequencing was published by SANGER et al. (Proc. Natl. Acad. Sci. USA (1977) 74(12):5463 5467). The Sanger method relies on enzymatic activity of a DNA polymerase to synthesize sequence dependent fragments of various lengths. The lengths of the fragments are determined by the random incorporation of dideoxynucleotide base-specific terminators. These fragments can then be separated in a gel as in the Maxam-Gilbert procedure, visualized, and the sequence determined. Numerous improvements have been made to refine the above methods and to automate the sequencing procedures. Similarly, RNA sequencing methods are also known. For example, reverse transcriptase with dideoxynucleotides have been used to sequence encephalomyocarditis virus RNA (ZIMMERN D. and KAESBERG P. Proc. Natl. Acad. Sci. USA (1978) 75(9):4257-4261). MILLS DR. and KRAMER FR. (Proc. Natl. Acad. Sci. USA (1979) 76(5):2232-2235) describe the use of QP replicase and the nucleotide analog inosine for sequencing RNA in a chain-termination mechanism. Direct chemical methods for 38 WO 2012/162812 PCT/CA2012/000529 sequencing RNA are also known (PEATTIE DA. Proc. Natl. Acad. Sci. USA (1979) 76(4):1760-1764). Other methods include those of Donis-Keller et al. (1977, Nucl. Acids Res. 4:2527-2538), SIMONCSITS A. et al. (Nature (1977) 269(5631):833-836), AXELROD VD. et al. (Nucl. Acids Res.(1978) 5(10):3549 3563), and KRAMER FR. and MILLS DR. (Proc. Natl. Acad. Sci. USA (1978) 75(11):5334-5338). Nucleic acid sequences can also be read by stimulating the natural fluoresce of a cleaved nucleotide with a laser while the single nucleotide is contained in a fluorescence enhancing matrix (U.S. Pat. # 5,674,743); In a mini sequencing reaction, a primer that anneals to target DNA adjacent to a SNP is extended by DNA polymerase with a single nucleotide that is complementary to the polymorphic site. This method is based on the high accuracy of nucleotide incorporation by DNA polymerases. There are different technologies for analyzing the primer extension products. For example, the use of labeled or unlabeled nucleotides, ddNTP combined with dNTP or only ddNTP in the mini sequencing reaction depends on the method chosen for detecting the products. Probes used in hybridization can include double-stranded DNA, single-stranded DNA and RNA oligonucleotides, and peptide nucleic acids. Hybridization methods for the identification of single nucleotide polymorphisms or other mutations involving a few nucleotides are described in the U.S. Pat. 6,270,961; 6,025,136; and 6,872,530. Suitable hybridization probes for use in accordance with the invention include oligonucleotides and PNAs from about 10 to about 400 nucleotides, alternatively from about 20 to about 200 nucleotides, or from about 30 to about 100 nucleotides in length. A template-directed dye-terminator incorporation with fluorescent polarization-detection (TDI-FP) method is described by FREEMAN BD. et al. (J Mol Diagnostics (2002) 4(4):209-215) for large scale screening. Oligonucleotide ligation assay (OLA) is based on ligation of probe and detector oligonucleotides annealed to a polymerase chain reaction amplicon strand with detection by an enzyme immunoassay (VILLAHERMOSA ML. J Hum Virol (2001) 4(5):238-48; ROMPPANEN EL. Scand J Clin Lab Invest (2001) 61(2):123-9; IANNONE MA. et al. Cytometry (2000) 39(2):131-40). Ligation-Rolling Circle Amplification (L-RCA) has also been successfully used for genotyping single nucleotide polymorphisms as described in QI X. et al. Nucleic Acids Res (2001) 29(22):El 16. 5' nuclease assay has also been successfully used for genotyping single nucleotide polymorphisms (AYDIN A. et al. Biotechniques (2001) (4):920-2, 924, 926-8.). 39 WO 2012/162812 PCT/CA2012/000529 Polymerase proofreading methods are used to determine SNPs identities, as described in WO 0181631. Detection of single base pair DNA mutations by enzyme-amplified electronic transduction is described in PATOLSKY F et al. Nat Biotech. (2001) 19(3):253-257. Gene chip or microarray technologies are also known for single nucleotide polymorphism discrimination whereby numerous polymorphisms may be tested for simultaneously on a single array (for example: EP 1120646; and GILLES PN. et al. Nat. Biotechnology (1999) 17(4):365-70). Matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy is also useful in the genotyping single nucleotide polymorphisms through the analysis of microsequencing products (HAFF LA. and SMIRNOV IP. Nucleic Acids Res. (1997) 25(18):3749-50; HAFF LA. and SMIRNOV IP. Genome Res. (1997) 7:378-388; SUN X. et al. Nucleic Acids Res. (2000) 28 e68; BRAUN A. et al. Clin. Chem. (1997) 43:1151-1158; LITTLE DP. et al. Eur. J. Clin. Chem. Clin. Biochem. (1997) 35:545 548; FEI Z. et al. Nucleic Acids Res. (2000) 26:2827-2828; and BLONDAL T. et al. Nucleic Acids Res. (2003) 31(24):e155). Sequence-specific PCR methods have also been successfully used for genotyping single nucleotide polymorphisms (HAWKINS JR. et al. Hum Mutat (2002) 19(5):543-553). Alternatively, a Single Stranded Conformational Polymorphism (SSCP) assay or a Cleavase Fragment Length Polymorphism (CFLP) assay may be used to detect mutations as described herein. US 7,074,597 describes methods for multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry. Nucleotide identity is detected at a specific site of a nucleic acid sample by contacting DNA-primer complex with labeled dideoxynucleotides (ddNTPs) to generate labeled single base extended (SBE) primer. The identifying ddNTP may be within the SBE primer. Multiplex analysis of PCR-amplified products may also be used to detect specific SNPs. Reporting DNA sequences comprising a fluorophore on a 5' end may be used to combine a multiplex PCR amplification reaction with microsphere based hybridization (US 7,083,951). Other multiplex detection methods include BeadArraym and similar hybridization-based methods, for example, those described in US Patent Nos. 6,429,027, 6,396,995, 6,355,431. 40 WO 2012/162812 PCT/CA2012/000529 Microarray or 'gene chips' of oligonucleotides may be used for SNP discrimination. Oligonucleotides may be nucleic acids or modified nucleic acids, including PNAs, and may be 'spotted' onto a solid matrix, such as a glass or plastic slide. Alternatively, oligonucleotides may be synthesized in situ on the slide. See, for example, GAO et al 2004. Biopolymers 73:579-596; US 5,445,934; US 5,744,305, US 5,800,992, US 5,796,715. Alternatively, if a subject's sequence data is already known, then obtaining may involve retrieval of the subjects nucleic acid sequence data (for example from a database), followed by determining or detecting the identity of a nucleic acid or genotype at a polymorphic site by reading the subject's nucleic acid sequence at the one or more polymorphic sites. Once the identity of a polymorphism(s) is determined or detected an indication may be obtained as to the subject's risk of cardiotoxicity following anthracycline administration. Methods for predicting a subject's risk of cardiotoxicity following anthracycline administration may be useful in making decisions regarding the administration of anthracycline(s). TREATMENT Anthracycline compounds (for example, doxorubicin) may be used to treat a variety of cancers in children and adults. In a given therapeutic regimen, the anthracycline compound may be administered alone or in combination with other chemotherapeutic agents in various doses and compositions, depending on the type of cancer, age of subject, health of subject, body mass, etc. The choice of dose, chemotherapeutic agents or combinations, methods of administration and the like will be known to those skilled in the art. Further, methods of assessing response to treatment and side effects are also known. For example, heart function in a subject suspected of experiencing cardiotoxicity may be assessed by various methods including medical history, electrocardiogram (ECG) monitoring, endomyocardial biopsy, radionuclide angiography (MUGA scan) or LVEF monitoring with serial echo or exercise stress testing, or other methods that may be dependent on the age and condition of the subject, as are known in the art. Early signs of cardiotoxicity may include persistent reduction in the voltage of the QRS wave, prolongation of the systolic time interval, or reduction of LVEF as determined by echo or MUGA. A reduction of 10% to below the lower limit of normal, 20% at any level, or an absolute LVEF < 45% indicates deterioration of cardiac function.) Response to a therapeutic regimen may be monitored. Tumor staging provides a method to assess the size and spread of a tumor in response to a treatment regimen. The TNM tumor staging system uses three 41 WO 2012/162812 PCT/CA2012/000529 components to express the anatomic extent of disease: T is a measure of the local extent of tumor spread (size), N indicates the presence or absence of metastatic spread to regional lymph nodes, and M specifies the presence or absence of metastatic spread to distant sites. The combination of these classifications combine to provide a stage grouping. Clinical TNM (cTNM) defines the tumor based on clinical evidence. Pathologic TNM (pTNM) defines the tumor based on examination of a surgically resected specimen. Changes in tumor size may be observed by various imaging methods known to physicians or surgeons in the field of oncology therapy and diagnostics. Examples of imaging methods include positron emission tomography (PET) scanning, computed tomography (CT) scanning, PET/CT scanning, magnetic resonance imaging (MRI), chemical shift imaging, radiography, bone-scan, mammography, fiberoptic colonoscopy or ultrasound. Contrast agents, tracers and other specialized techniques may also be employed to image specific types of cancers, or for particular organs or tissues, and will be known to those skilled in the art. Changes in rate of metastasis may also be observed by the various imaging methods, considering particularly the appearance, or frequency of appearance, of tumors distal to the primary site. Alternatively, the presence of tumor cells in lymph nodes adjacent and distal to the primary tumor site may also be detected and used to monitor metastasis. A subject may be tested for a cardiotoxicity-associated polymorphism before undergoing a therapeutic regimen involving an anthracycline compound. If a subject's genotype includes a cardiotoxicity associated polymorphism, this may indicate that the subject is at a risk for cardiotoxicity when an anthracycline compound is administered. A subject at risk for cardiotoxicity may be administered a therapeutic regimen involving an anthracycline compound and the cardiac function monitored as described. If a decrease in cardiac function is identified, the therapeutic regimen may be altered to decrease the dose of the anthracycline compound, eliminate the dose of the anthracycline compound, or increase the dose of a second chemotherapeutic agent in the therapeutic regimen. Examples of chemotherapeutic agents that may be used in combination with an anthracycline compound in a therapeutic regimen may include, for example, cyclophosphamide, Ifosphamide, fluorouracil, Paclitaxel, vincristine, cisplatin, streptozocin, docetaxel, and the like. A subject at risk for cardiotoxicity may also be administered a therapeutic regimen involving an anthracycline compound and the cardiac function monitored as described. The therapeutic regimen may be supplemented to include a cardioprotective agent. Examples of cardioprotective agents are known in 42 WO 2012/162812 PCT/CA2012/000529 the art, and may include those described by Wouters et al 2005. Br. J Hematol 131:561-578). For example, Dexrazoxane is a cardioprotective agent and is approved for use in conjunction with doxorubicin to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration. Alternatively, a subject at risk for cardiotoxicity may be administered a therapeutic regimen that does not involve an anthracycline compound and the cardiac function monitored as described. GENES Numerous genes are known to be involved in ADME (absorption, distribution, metabolism and elimination), for example UGT1A6, SULT2B1, SLC28A3, SLC28A1, SLC22Al7, SLC22A7, ABCB4, and HNMT. Detailed information relating to the sequence, expression patterns, molecular biology, etc of these and related genes in both Homo sapiens and in other model species is known, and may be found at, for example Entrez Gene (http://www.ncbi.nlm.nih.gov) and references therein. UDP glucuronosyltransferase 1 family, polypeptide A6 [Homo sapiens] (UGT1 A6) (alternate names include GNT1, HLUGP, HLUGP1, MGC29860, UDPGT, UDPGT 1-6, UGT1, UGT1A6S, UGT1F, phenol-metabolizing UDP-glucuronosyltransferase) maps to chromosome 2q37. Examples of nucleic acid sequences comprising UGT1A6 include those found in the NCBI Entrez Gene database by accession number NM 001072, NC_000002.1 1. UGTIA6 encodes an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water soluble, excretable metabolites. The UGT1A6 gene is part of a complex locus that encodes several UDP glucuronosyltransferases and includes 13 unique alternate first exons followed by four common exons. Nine of the 5' exons may be spliced to the four common exons, resulting in nine proteins with different N termini and identical C-termini and the remaining four alternate first exons are considered pseudogenes. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenolic and planar compounds and alternative splicing in the unique 5' end of this gene results in two transcript variants. Sulfotransferase family, cytosolic, 2B, member 1 [Homo sapiens] (SULT2B1) (alternate names include HSST2) maps to chromosome 19q13.3. Examples of nucleic acid sequences comprising SULT2B1 include NC_000019.9, NG_029063.1, and AK096418.1. Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. SULT2Blis a cytosolic enzyme and has variable tissue distributions and substrate specificities. This gene sulfates 43 WO 2012/162812 PCT/CA2012/000529 dehydroepiandrosterone but not 4-nitrophenol, a typical substrate for the phenol and estrogen sulfotransferase subfamilies. Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3' [Homo sapiens] (SLC28A3) (alternate names include concentrative Na+-nucleoside cotransporter; concentrative nucleoside transporter 3; CNT3) maps to chromosome 9q22.2. The genomic region (chromosome) can be accessed in the NCBI Entrez Genome database by accession number NC_000009, about nucleotides (complement) 86082912 86173233 (in version NC_000009.10 GI:89161216, genome annotation build 36 version 3). Examples of nucleic acid sequences comprising SLC28A3 include those found in the NCBI Entrez Gene database by accession number NM_022127 (gene ID 64078), and the Ensembl database by gene ID ENSGOOO 197506. SLC28A3 shows broad specificity for pyrimidine and purine nucleosides. Nucleoside transporters, such as SLC28A3, regulate multiple cellular processes, including neurotransmission, vascular tone, adenosine concentration in the vicinity of cell surface receptors, and transport and metabolism of nucleoside drugs. Solute carrier family 28 (sodium-coupled nucleoside transporter), member l' [Homo sapiens] (SLC28A1) (alternate names include human Organic Cation Transporter 1; hOCTl) maps to chromosome 6q26. The genomic region (chromosome) can be accessed in the NCBI Entrez Genome database by accession number NC_000006.10, about nucleotides (complement) 160462853-160499740. Examples of nucleic acid sequences comprising SLC28A1 include those found in the NCBI Entrez Gene database by accession number U77086 (gene ID 6580), and the Ensembl database by gene ID ENSG0000175003. SLC28A1 is one of three similar cation transporter genes located in a cluster on chromosome 6. Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are involved in elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. The encoded SLC28Al protein contains twelve putative transmembrane domains and is a plasma integral membrane protein. Two transcript variants encoding two different isoforms have been found for this gene, but only the longer variant encodes a functional transporter. Solute carrier family 22, member 17 [ Homo sapiens ] (SLC22A17) (alternate names include BOCT; BOIT; 24p3R; NGALR; hBOIT; NGALR2; NGALR3) maps to chromosome 14ql 1.2. Examples of nucleic acid sequences comprising SLC22A17 include NC 000014.8, NM_016609, AJ243653.1 and BCl 11015.1. Isoform b is encoded by transcript variant 2, solute carrier family 22 (organic cation transporter), member 17 and is reported to be a potent brain type organic ion transporter, NGAL receptor, 44 WO 2012/162812 PCT/CA2012/000529 neutrophil gelatinase-associated lipocalin receptor, brain-type organic cation transporter, 24p3 receptor, and lipocalin-2 receptor. Solute carrier family 22, member 7 [ Homo sapiens ] (SLC22A7) (alternate names include organic anion transporter) maps to chromosome 6p2l.1. Examples of nucleic acid sequences comprising SLC22A7 include NM_153320, NM_006672.3, EU562669.1 and BC0 17963.1. SLC22A7 mediates the uptake of organic anions such as salicylate, acetylsalicylate, prostaglandin E2, dicarboxylates, and p aminohippurate. Salicylate uptake is saturable and sodium-independent. SLC22A7 is thought to be a multispecific organic anion transporter of the liver. ATP-binding cassette, sub-family B (MDR/TAP), member 4 [Homo sapiens] (ABCB4) (alternate names include P-GLYCOPROTEIN 3; PGY3, MULTIDRUG RESISTANCE 3; MDR3), maps to chromosome 7q21.12 and ABCB4 gene has been determined to have 28 exons over 74 kb. Examples of nucleic acid sequences comprising ABCB4 include NM_018849.2 (variant B), NM_000443.3(variant A), NM_018850.2 (variant C) and NG_007118.1. P-glycoproteins are thought to act as pumps for the extrusion of drugs from cells at the cost of ATP hydrolysis. P-glycoproteins belong to a class of vectorial transport proteins known as the ATP-binding cassette transporter proteins. These pumps are thought to be a defense against xenobiotic. The P-glycoproteins have 2 homologous halves, each with 6 hydrophobic segments adjacent to a consensus sequence for nucleotide binding. The hydrophobic segments are thought to form a membrane channel, whereas the nucleotide binding site may be involved in energization of drug transport. Histamine n-methyltransferase [Homo sapiens] (HNMT) maps to chromosome 2q22. 1. Examples of nucleic acid sequences comprising HNMT include NG_012966, NM_001024074.2 (variant 2), NM_001024075.1 (variant 3), NM_006895.2 (variant 1), and AH012839.2. Histamine is metabolized in most mammals by HNMT and diamine oxidase (DAO), but the relative contributions of these 2 enzymes to histamine metabolism is different depending on the tissue. HNMT plays the dominant role in histamine biotransformation in bronchial epithelium and has been associated with susceptibility to asthma. There are large individual variations of HNMT activity in human tissues. Biochemical genetic studies of red blood cell HNMT has demonstrated that 5-fold differences among individuals in levels of HNMT activity are due primarily to the effects of inheritance. 45 WO 2012/162812 PCT/CA2012/000529 EXAMPLES EXAMPLE 1 - multi-SNP Panel Methods for EXAMPLE 1 Samples Study participants were recruited through the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a multicenter active surveillance consortium studying adverse drug reactions in children (Carleton, B. et al. Pharmacoepidemiol Drug Saf (2009) 18:713-721). The current replication cohort for this example (n=218) consisted of a new Canadian CPNDS replication cohort that was recruited from pediatric oncology units and long-term follow-up clinics across Canada between February 2010 and April 2011 and the Dutch-EKZ cohort that was recruited at the Emma Children's Hospital/Academic Medical Centre in Amsterdam, the Netherlands, between July 2009 and April 2011 (van der Pal, H.J. et al. Arch Intern Med (2010) 170:1247-1255 ; and van Dalen, EC. et al. Eur J Cancer (2006) 42:3191-3198). This replication cohort was used to replicate the previous genetic findings and to test the prediction models (see below). The previous cohort, which consisted of the two initial Canadian cohorts (discovery and replication) (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011), was used in the combined analysis and training of the prediction model (see below) and has been described previously (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). Study cohorts consisted of patients who developed cardiotoxicity during or after treatment with anthracyclines for childhood cancer (cases) and patients who received anthracyclines, but did not show cardiotoxicity (controls). In the Dutch-EKZ cohort cases and controls were matched for age, gender and cumulative dose where possible and follow-up time in controls was matched with time to first available echocardiogram showing cardiotoxicity in cases. ACT was defined as early- or late-onset left ventricular dysfunction measured by echocardiogram (shortening fraction, SF) and/or symptoms requiring intervention based on CTCAEv3 (Common Terminology Criteria for Adverse Events) (Cancer Therapy Evaluation Program - Common Terminology Criteria for Adverse Events - Version 3. In Edition 2003). To improve differentiation between cardiotoxicity cases and controls a more stringent SF threshold of :26% at any time during or after anthracycline therapy was used to define cardiotoxicity. Only echocardiograms obtained 221 days after a dose of anthracyclines were used to exclude transient acute cardiotoxicity. Control patients were defined as those having normal echocardiograms (SF>30%) during and after therapy, with a follow-up of >5 years after completion of anthracycline therapy. Cumulative anthracycline doses were calculated using doxorubicin equivalents (Altman, A.J. Children's Oncology Group. Supportive care of children with 46 WO 2012/162812 PCT/CA2012/000529 cancer: current therapy and guidelines from the Children's Oncology Group. Baltimore: Johns Hopkins University Press 2004). Written informed consent or assent was obtained from each subject or their parents or legal guardians. The study was approved by the ethics committees of all participating universities and hospitals. Genotyping Twenty-three SNPs were selected that previously showed evidence of association (P<0.01) with ACT (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). Genomic DNA was extracted from blood, saliva or buccal swabs using the QIAampTM DNA purification system (QiagenTM, Canada). DNA samples were genotyped using a custom 96-plex Illumina Veracode GoldenGateTM SNP genotyping assay according to manufacturer's instructions (IlluminaTM, San Diego, USA). This assay included an additional 63 non-study SNPs used for quality control (QC) purposes only. All SNP genotypes were manually clustered using Illumina GenomeStudioTM software. One SNP in FMO2 (rs2020870) could not be reliably clustered and was therefore removed from further analyses. Two non-study SNPs with a SNP call rate of <95% were also removed. Sixteen samples (2 cases and 14 controls) with a call rate of <95% were removed. The remaining 202 samples had an average call rate of 99.7%. All 22 remaining study SNPs had a SNP call rate of >98% (mean 99.7%) and were in Hardy-Weinberg equilibrium (P>0.05). Power calculation and statistical analysis We calculated a priori to have 61-92% (mean 72%) statistical power to detect an association based on the previous effect sizes and allele frequencies and a two-sided type I error rate of 0.05 using QUANTOTM v1.2.4 software (Gauderman, W. and Morrison, J. QUANTO 1.lTM: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe. In Edition 2006). Clinical variables in cases and controls were compared using Fisher's exact test for proportional variables and Wilcoxon-Mann-Whitney rank-sum test for continuous variables. Hardy-Weinberg Equilibrium of the polymorphisms was tested using Fisher's Exact test in controls. The primary association test was a single SNP test assuming an additive genetic model using logistic regression with cumulative anthracycline dose, age, gender and radiation therapy to the heart included as covariates. As we had previously noted an effect of SLC28A3 rs7853758 only in patients who received doxorubicin and/or daunorubicin (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011), we decided a priori to conduct our primary analysis in the 192 (out of 218) patients who received doxorubicin and/or daunorubicin - of 47 WO 2012/162812 PCT/CA2012/000529 these, 177 were successfully genotyped. In order to have sufficient power to replicate the previous associations, the Dutch-EKZ and new Canadian CPNDS replication cohort were analyzed together. We also combined the initial cohorts (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011) and the current new cohorts to show the overall significance. Secondary association tests were stratified analyses that included clinical covariates not used to stratify (e.g. stratification by age-group did not include age as a covariate). For continuous variables, the median was used to define the subgroups. Heterogeneity between groups was assessed using Cochran's Q-statistic. A p-value of <0.05 was considered to be statistically significant. Multivariate logistic regression models including multiple genetic variants and/or clinical variables were all trained in the initial Canadian discovery and replication cohort combined (previous cohort) (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011) and tested in the current replication cohort (Dutch and new Canadian patients combined). Risk scores were calculated by multiplying each variable with the estimated beta (log odds ratio) from the training cohort. The previous full model was constructed using step-wise regression with forward selection, where 9 SNPs with P<0.01 were retained in the final model (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). The revised model was constructed to include the 5 SNPs that showed an effect in the same direction in the current replication cohort and that were more significant in the combined analysis than before as well as the clinical variables gender, age, anthracycline dose and radiation to the heart. One SNP in SLC28A3 (rs885004) was not included in this model as it was in high linkage disequilibrium (LD) with another SNP (rs7853758) as previously shown (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). Models were assessed by constructing Receiver Operating Characteristic (ROC) curves and calculating the c-statistic (Area Under the Curve AUC) using the risk scores from the model and the actual value (case or control). Statistical analyses were conducted using SNP and Variation Suite 7.4.5 (Golden HelixTM, Bozeman, USA) and R 2.13.0 (R Development Core Team). Patient baseline characteristics are provided in Table 3 for both the Dutch-EKZ and new Canadian replication cohort separately. Cumulative anthracycline doses were significantly different between cases and controls in both cohorts (P=0.0071 and P=0.000 17, respectively) - particularly in the Canadian cohort in which all cases received a higher dose than the median dose in controls. In addition, controls were significantly younger in the Canadian cohort (P=0.0 13). Furthermore, there were more acute myeloid leukemia among Canadian cases (P=0.0069), although the overall numbers were low. Finally, follow-up was significantly longer in cases in the Dutch-EKZ cohort (21.3 versus 16.8 years, P=0.012). 48 WO 2012/162812 PCT/CA2012/000529 TABLE 3. Subject Demographics Replication Cohorts Dutch-EKZ (n=128) Canadian-CPNDS (n=90) Cardiotoxicity Controls Cardiotoxicity Controls (n=44) (n=84) P-value (n=12) (n=78) P-value Age in yrs, median (range) 9.1 (0.5-16.8) 11.2 (1.8-17.7) 0.30 12.6 (0.9-17.0) 4.9 (0.5-16.0) 0.013 Gender, no. female (%) 21(48%) 40(48%) 1.00 4 (33%) 47(60%) 0.12 Dose in mg/rn 2 , median (range)a 360 (100-720) 280 (50-720) 0.0071 300 (175-550) 150 (50-540) 0.00017 Anthracycline type, no. (%) Doxorubicin 28 (64%) 46 (55%) 0.35 7 (58%) 59 (76%) 0.29 Daunorubicin 2 (5%) 6(7%) 0.71 2 (17%) 9 (12%) 0.64 Doxorubicin plus daunorubicin 2 (5%) 6 (7%) 0.71 1(8%) 7(9%) 1.00 Doxorubicin plus other 3 (7%) 8 (10%) 0.75 0(0%) 1 (1%) 1.00 Daunorubicin plus other 0(0%) 1 (1%) 1.00 2(17%) 2(3%) 0.08 Doxorubicin, daunorubicin plus other 0(0%) 0(0%) 1.00 0(0%) 0(0%) 1.00 Epirubicin 6(14%) 14 (17%) 0.80 0 (0%) 0 (0%) 1.00 Epirubicin plus other 3 (7%) 2 (2%) 0.34 0 (0%) 0 (0%) 1.00 Other 0(0%) 1 (1%) 1.00 0 (0%) 0(0%) 1.00 Tumor type, no. (%) Acute Lymphoblastic Leukemia 10 (23%) 14 (17%) 0.48 3 (25%) 29 (37%) 0.53 Acute Myelogenous Leukemia 0 (0%) 7 (8%) 0.09 3(25%) 1 (1%) 0.0069 Other Leukemia 0 (0%) 1 (1%) 1.00 1(8%) 2 (3%) 0.35 Hodgkin's Lymphoma 4 (9%) 10 (12%) 0.77 0 (0%) 9 (12%) 0.60 Non-Hodgkin's Lymphoma 10(23%) 19 (23%) 1.00 0(0%) 7 (9%) 0.59 Osteosarcoma 3 (7%) 11 (13%) 0.38 0(0%) 2 (3%) 1.00 Rhabdomyosarcoma 4 (9%) 4 (5%) 0.45 0 (0%) 3 (4%) 1.00 Ewing's sarcoma 6 (14%) 5 (6%) 0.19 1(8%) 2 (3%) 0.35 Other sarcoma 2 (5%) 1 (1%) 0.27 0(0%) 0(0%) 1.00 Nephroblastoma 3 (7%) 11 (13%) 0.38 3 (25%) 12(15%) 0.41 Hepatoblastoma 0(0%) 0(0%) 1.00 1(8%) 1 (1%) 0.25 Neuroblastoma 0(0%) 0(0%) 1.00 0(0%) 10(13%) 0.35 Carcinoma 2 (5%) 0(0%) 0.12 0(0%) 0(0%) 1.00 Germ Cell Tumor 0(0%) 1 (1%) 1.00 0(0%) 0(0%) 1.00 Radiotherapy involving heart, no. (%) 9 (20%) 19 (23%) 0.83 4 (33%) 18 (23%) 0.48 Follow-up in yrs, median (range) 21.3 (7.4-28.5) 16.8 (5.0-31.6) 0.012 6.8 (0.4-27.2) 7.4 (5.0-23.1) 0.81 Patient characteristics for the Dutch-EKZ and new Canadian replication cohort separately. For age, dose and follow-up, the Wilcoxon-Mann-Whitney test with normal approximation was used. For gender, anthracycline type, tumor type and radiotherapy involving the heart region, the Fisher exact test was used. In bold are statistically significant values at p<0.05.aCumulative anthracycline dose in doxorubicin isotoxic equivalent doses. bOther anthracycline type included idarubicin, epirubicin or mitoxantrone. TABLE 4. Association between SNPs and Anthracycline-Induced Cardiotoxicity Previous cohort (n=344) Current replication (n=177) Combined (n=521) 78 cases, 266 controls 46 cases, 131 controls 124 cases, 397 controls SNP rs-ID Gene Allele" OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value rs7853758 SLC28A3 A/G 0.31 (0.16 - 0.60) 0.00010 0.46 (0.20 - 1.08) 0.058 + 0.36 (0.22 - 0.60) 1.6E-05 49 WO 2012/162812 PCT/CA2012/000529 rs885004 SLC28A3 A/G 0.31 (0.15 - 0.62) 0.00021 0.42 (0.16 - 1.10) 0.058 + 0.34 (0.20 - 0.60) 3.OE-05 rs17863783 UGT1A6 A/C 3.68 (1.45 - 9.30) 0.0059 7.98 (1.85 - 34.4) 0.0062 + 4.30 (1.97 - 9.36) 2.4E-04 rs10426377 SULT2B1 A/C 0.54 (0.34 - 0.86) 0.0071 0.52 (0.26 - 1.04) 0.054 + 0.56 (0.38 - 0.81) 0.0015 rs2305364 SLC28AI A/G 1.76 (1.20 - 2.58) 0.0033 1.48 (0.88 - 2.51) 0.14 + 1.60 (1.18 - 2.17) 0.0020: rs4148350 ABCC1 A/C 3.44 (1.65 - 7.15) 0.0012 1.29 (0.48 - 3.47) 0.61 + 2.40 (1.33 - 4.33) 0.0040 rs17645700 HNMT G/A 0.46 (0.26 - 0.82) 0.0053 0.70 (0.36 - 1.36) 0.29 + 0.56 (0.37 - 0.86) 0.0054 rs9514091 SLC10A2 A/G 0.43 (0.23 - 0.78) 0.0033 0.77 (0.41 - 1.46) 0.42 + 0.57 (0.38 - 0.87) 0.0063 rs4148808 ABCB4 A/G 1.86 (1.17 - 2.96) 0.0093 1.41 (0.72 - 2.77) 0.33 + 1.67 (1.15 - 2.43) 0.0072 rs17583889 HNMT A/C 1.91 (1.21 - 3.02) 0.0057 1.26 (0.65 - 2.46) 0.50 + 1.67 (1.15 - 2.41) 0.0073 rs2290271 SLC28A1 C/A 0.56 (0.37 - 0.83) 0.0035 0.80 (0.46 - 1.39) 0.43 + 0.66 (0.48 - 0.91) 0.0098 rs1736557 FMO3 A/G 0.33 (0.13 - 0.81) 0.0060 0.67 (0.25 - 1.79) 0.41 + 0.47 (0.25 - 0.87) 0.011 rs2019604 SPG7 C/A 0.39 (0.20 - 0.76) 0.0021 0.84 (0.39 - 1.80) 0.64 + 0.56 (0.35 - 0.90) 0.012 rs7319981 SLC10A2 A/G 0.51 (0.32 - 0.81) 0.0029 0.93 (0.54 - 1.59) 0.78 + 0.66 (0.47 - 0.93) 0.016 rs4261716 UGT1A6 A/C 1.76 (1.19 - 2.59) 0.0043 1.02 (0.60 - 1.74) 0.93 + 1.44 (1.06 - 1.95) 0.018 rs6759892 UGT1A6 C/A 1.77 (1.20 - 2.61) 0.0038 0.99 (0.58 - 1.69) 0.96 1.43 (1.05 - 1.94) 0.022 rs2235047 ABCB1 C/A 2.92 (1.31 - 6.49) 0.0087 1.34 (0.51 - 3.49) 0.56 + 1.79 (1.05 - 3.04) 0.036 rs4877847 SLC28A3 A/C 0.60 (0.41 - 0.89) 0.0092 1.06 (0.61 - 1.84) 0.83 0.73 (0.54 - 0.98) 0.037 rs729147 ADH7 G/A 1.86 (1.18 - 2.93) 0.0072 0.94 (0.50 - 1.74) 0.83 1.43 (1.02 - 2.01) 0.041 rsl 149222 ABCB4 C/A 1.87 (1.20 - 2.92) 0.0054 0.89 (0.49 - 1.61) 0.69 1.36 (0.97 - 1.90) 0.075 rs2108623 CYP4F11 G/A 0.57 (0.38 - 0.86) 0.0055 1.17 (0.68 - 1.99) 0.57 0.77 (0.57 - 1.04) 0.084 rs316019 SLC22A2 A/C 0.40 (0.20 - 0.81) 0.0049 1.90 (0.89 - 4.05) 0.10 0.75 (0.46 - 1.21) 0.23 Results from initial cohorts from previous study combined (previous cohort) compared to the current replication cohort as well as all cohorts combined. In the current replication cohort, only patients that received doxorubicin and/or daunorubicin were included. Odds ratios are per copy of the minor allele. Plus (+) sign indicates result in same direction in replication cohort. Star (*) sign indicates result more significant in combined cohort than in previous cohort. "SNP alleles assayed; minor allele is mentioned first; P-values in bold are significant after multiple testing correction in combined cohort; SNP, Single Nucleotide Polymorphism; repl, replication; OR, Odds Ratio; CI, Confidence Interval. The present results confirm the previous association between rs17863783 in UGT1A6 and ACT (P=0.0062; odds ratio (OR) 7.98 - Table 4). Furthermore, two SNPs in SLC28A3 (rs7853758 and rs885004) and one in SULT2B1 (rs10426377) were close to being significantly associated in the current replication cohort (P=0.058, P=0.058 and P=0.054, respectively). The two SLC28A3 SNPs were also significantly associated with ACT in a combined analysis of the initial and current cohorts after applying the same threshold for multiple testing as previously defined (P<0.00015) (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011), while rs17863783 showed a trend (P corrected = 0.078). In total, 16 out of 22 SNPs showed an effect in the same direction (Table 4), which is significantly higher than expected by chance alone (P=0.026). Six SNPs were also more significantly associated in all cohorts combined than in the previous cohort (Table 4). Including patients that did not receive doxorubicin or 50 WO 2012/162812 PCT/CA2012/000529 daunorubicin, but received other anthracyclines instead, yielded similar, though slightly less significant results (see Table 8). We assessed whether our definition of cardiotoxicity using a threshold of SF526% influenced our results by performing a subgroup analysis of patients with more severe cardiotoxicity (SF<24% or symptoms, CTCAE grade 2-4). Again, similar results were obtained with comparable effect sizes (results not shown). Interestingly, in the combined cohort of severe cardiotoxicity, UGT1A6 rsl7863783 now was significantly associated with ACT after correcting for multiple testing (P corrected = 0.036). Next, we explored whether the effects of these variants were influenced by gender, age or cumulative anthracycline dose (effect-size heterogeneity) which could explain some of the differences in susceptibility to ACT. In females, two variants in ABCB4 (rs4148808 and rsl 149222) were associated with increased risk for ACT (P=0.00067 and P=0.0024 respectively), while these variants had no effect in males (P=0.81 and P=0.65) which was significantly different (Phet=0.028 and Phet=0.0 12, respectively Table 5). Conversely, SULT2B1 variant rs10426377 only had an effect in males (P=0.00021), but not in females (P=0.42; Phet=0.033). None of the other variants showed significant gender-specific effects (P>0.05). Similarly, in younger children (<5.3 years), HNMT variant rsl7583889 was associated with increased ACT (P=0.00025), while this effect was not detected in older children (P=0.59; Phet=0.0022 Table 6). A similar pattern was observed for rs316019 in SLC22A2 (P=0.0021 versus P=0.59, Phet=0.016), though this SNP did not replicate in the current replication cohort (Table 4). No statistically significant different effect-sizes were detected for any genetic variant between higher and lower cumulative dose groups (results not shown). TABLE 5. Association between SNPs and anthracycline-induced cardiotoxicity by gender Female (n=248) Male (n=273) 59 cases, 189 controls 65 cases, 208 controls SNP rs-ID Gene Allelea OR (95% CI) P-value OR (95% CI) P-value Phet-value rs1149222 ABCB4 C/A 2.18 (1.31-3.60) 0.0024 0.89 (0.56-1.44) 0.65 0.012 rs4148808 ABCB4 A/G 2.53 (1.47-4.36) 0.00067 1.07 (0.62-1.85) 0.81 0.028 rs10426377 SULT2B1 A/C 0.82 (0.50-1.34) 0.42 0.35 (0.20-0.64) 0.00021 0.033 rs1736557 FMO3 A/G 0.76 (0.33-1.76) 0.52 0.25 (0.08-0.72) 0.0024 0.10 rs4148350 ABCCI A/C 1.33 (0.47-3.80) 0.60 3.18 (1.48-6.82) 0.0027 0.19 rs17583889 HNMT A/C 1.34 (0.76-2.33) 0.31 2.19 (1.30-3.69) 0.0029 0.20 rs2108623 CYP4F11 G/A 0.92 (0.60-1.41) 0.70 0.64 (0.41-0.99) 0.041 0.25 rs885004 SLC28A3 A/G 0.48 (0.22-1.04) 0.048 0.27 (0.12-0.62) 0.00028 0.33 rs2019604 SPG7 C/A 0.69 (0.34-1.38) 0.27 0.45 (0.23-0.87) 0.012 0.39 51 WO 2012/162812 PCT/CA2012/000529 rs4261716 UGT1A6 A/C 1.27 (0.82-1.96) 0.28 1.62 (1.05-2.49) 0.029 0.44 rs7853758 SLC28A3 A/G 0.45 (0.22-0.92) 0.019 0.31 (0.15-0.64) 0.00034 0.45 rs6759892 UGTIA6 C/A 1.26 (0.82-1.95) 0.29 1.59 (1.03-2.46) 0.036 0.47 rs729147 ADH7 G/A 1.54 (0.97-2.44) 0.069 1.19 (0.71-2.00) 0.51 0.47 rs316019 SLC22A2 A/C 0.65 (0.33-1.28) 0.19 0.91 (0.46-1.81) 0.79 0.49 rs2235047 ABCB1 C/A 2.18 (1.01-4.72) 0.053 1.54 (0.73-3.25) 0.26 0.53 rs9514091 SLC1OA2 A/G 0.50 (0.27-0.93) 0.022 0.62 (0.35-1.09) 0.089 0.61 rs17863783 UGT1A6 A/C 5.00 (1.56-16.0) 0.0047 3.62 (1.22-10.7) 0.025 0.69 rs4877847 SLC28A3 A/C 0.74 (0.48-1.15) 0.18 0.68 (0.45-1.04) 0.074 0.79 rs17645700 HNMT G/A 0.60 (0.33-1.08) 0.078 0.54 (0.30-0.99) 0.037 0.83 rs2290271 SLC28A1 C/A 0.69 (0.44-1.09) 0.10 0.65 (0.41-1.02) 0.055 0.85 rs7319981 SLC1OA2 A/G 0.67 (0.41-1.11) 0.11 0.65 (0.40-1.04) 0.068 0.91 rs2305364 SLC28A1 A/G 1.59 (1.02-2.47) 0.038 1.58 (1.04-2.41) 0.032 0.99 Results from all cohorts combined. Odds ratios are per copy of the minor allele. In bold are statistically significant values at P<0.05. aSNP alleles assayed; minor allele is mentioned first; SNP, Single Nucleotide Polymorphism; OR, Odds Ratio; CI, Confidence Interval; Phe, P-value for heterogeneity. TABLE 6. Association between SNPs and anthracycline-induced cardiotoxicity by age-group <5.3 years (n=257) >5.3 years (n=264) 45 cases, 212 controls 79 cases, 185 controls SNP rs-ID Gene Allelea OR (95% CI) P-value OR (95% CI) P-value Phet-value rs17583889 HNMT A/C 3.53 (1.79-6.93) 0.00025 1.13 (0.72-1.79) 0.59 0.0022 rs316019 SLC22A2 A/C 0.16 (0.03-0.71) 0.0021 1.16 (0.68-2.00) 0.59 0.016 rs2235047 ABCB1 C/A 1.97 (0.81-4.76) 0.14 1.42 (0.73-2.74) 0.31 0.069 rs4148350 ABCCl A/C 4.66 (1.85-11.7) 0.0015 1.57 (0.74-3.33) 0.24 0.089 rs17645700 HNMT G/A 0.36 (0.16-0.81) 0.0062 0.67 (0.40-1.11) 0.11 0.13 rs1736557 FMO3 A/G 0.85 (0.28-2.52) 0.76 0.39 (0.18-0.84) 0.0087 0.15 rs9514091 SLC1OA2 A/G 0.41 (0.19-0.90) 0.017 0.69 (0.42-1.14) 0.14 0.30 rs1149222 ABCB4 C/A 1.44 (0.82-2.54) 0.21 1.22 (0.80-1.87) 0.36 0.34 rs6759892 UGT1A6 C/A 1.26 (0.77-2.05) 0.35 1.50 (1.01-2.23) 0.046 0.38 rs4261716 UGT1A6 A/C 1.27 (0.78-2.07) 0.33 1.53 (1.03-2.27) 0.036 0.40 rs4148808 ABCB4 A/G 1.43 (0.77-2.67) 0.26 1.66 (1.04-2.66) 0.036 0.52 rs2290271 SLC28A1 C/A 0.53 (0.29-0.97) 0.033 0.73 (0.50-1.08) 0.11 0.52 rs2108623 CYP4F11 G/A 0.63 (0.37-1.07) 0.084 0.87 (0.60-1.25) 0.45 0.52 rs2019604 SPG7 C/A 0.49 (0.19-1.22) 0.099 0.61 (0.35-1.08) 0.077 0.60 rs7319981 SLCIOA2 A/G 0.61 (0.34-1.08) 0.080 0.72 (0.47-1.10) 0.12 0.66 rs4877847 SLC28A3 A/C 0.63 (0.37-1.07) 0.080 0.75 (0.52-1.10) 0.14 0.66 rs7853758 SLC28A3 A/G 0.34 (0.13-0.89) 0.014 0.37 (0.20-0.68) 0.00043 0.68 rs10426377 SULT2B1 A/C 0.62 (0.34-1.14) 0.11 0.55 (0.35-0.87) 0.0080 0.74 rs17863783 UGT1A6 A/C 2.63 (0.68-10.2) 0.18 5.51 (1.93-15.7) 0.00070 0.78 rs885004 SLC28A3 A/G 0.44 (0.16-1.20) 0.080 0.31 (0.16-0.62) 0.00018 0.82 rs729147 ADH7 G/A 1.41 (0.80-2.49) 0.24 1.46 (0.95-2.24) 0.087 0.92 52 WO 2012/162812 PCT/CA2012/000529 rs2305364 SLC28A1 A/G 1.81 (1.07-3.06) 0.025 1.45 (1.00-2.11) 0.051 0.98 Results from all cohorts combined. Odds ratios are per copy of the minor allele. In bold are statistically significant values at P<0.05. aSNP alleles assayed; minor allele is mentioned first; SNP, Single Nucleotide Polymorphism; OR, Odds Ratio; Cl, Confidence Interval; Phei, P-value for heterogeneity. An earlier risk prediction model incorporated multiple genetic variants as well as clinical risk factors. To assess the ability of this model to discriminate between cases and controls, we applied this model to the current replication cohort and performed ROC analyses (Table 7). We revised the previous model to include only SNPs that replicated in the same direction and were more significant in the combined cohort (Table 4). The revised model, that included 5 SNPs and clinical variables, was trained in the previous cohort and then tested in the current replication cohort. In the training set, the full (clinical plus genetic) revised model performed better than the clinical-only model (AUC 0.771 versus 0.685; P=0.0031; Table 7). In the test set (current replication cohort), similar metrics were obtained with the full model discriminating better between cases and controls than the clinical-only model (AUC 0.767 versus 0.688) which was close to being significant (P=0.060). TABLE 7. AUCs of different models in training and test sets AUC (95% CI) Training set Test set Model Previous cohort Current Replication Previous model Clinical only 0.679 (0.614-0.745) 0.670 (0.584-0.755) Genetic only (9 SNPs) 0.814 (0.764-0.865) 0.570 (0.473-0.666) Full (clinical + genetic) 0.867 (0.820-0.913) 0.671 (0.579-0.763) Revised model Clinical only 0.685 (0.619-0.751) 0.688 (0.604-0.772) Genetic only (5 SNPs) 0.711 (0.646-0.776) 0.651 (0.561-0.741) Full (clinical + genetic) 0.771 (0.710-0.831) 0.767 (0.688-0.846) AUCs for different models in training set (previous cohort) and test set (current replication cohort). Clinical only model includes age at start of treatment, cumulative dose, gender, radiation therapy involving the heart region. Full model includes the clinical variables as well as the genetic variants, while the genetic-only model contains only the genetic variants. AUC, Area Under the Curve; CI, Confidence Interval; disc., discovery; repl., replication; SNP, Single Nucleotide Polymorphism. It is shown herein that combining the replicated variants with clinical risk factors in an optimized risk prediction model allowed for better discrimination between cases and controls than clinical risk factors alone in both the training as well as the test cohort. 53 WO 2012/162812 PCT/CA2012/000529 0 o c c> :, C If) L) . o - 0 0 ~fl C~- N - - - - CN - - - - -~ - ' - - u u 0 m r- 7, m'- V t,t- . - -t Cc o t:C ___ C C) C> C>C -0 00c C) +, +) + . . . . 0 kr M C)C C0 W)m c c T: I V > C- ) cC4 cV)r 14t x W 0 0nC)0 t-C )0 00c --- c-- ,cxV-O ri t- W) 0) CNm 0 r ) C4 4T l C: C:)O 0 000:>0C5000500 o C: 5CSoC)C: C ; C) 00 W)r .) r r T N)r 0 ~ o~ Q o r) mHl\~ N rnm ) 0 N 0 xO-00O 0 rcOO )-" C>~~~~ ~ ~ ~ ~ C>C : >0a 0 a) o 0 Q COO0~~~NO0U 0 0 ~ ~ NC r C C ) N c r - (f)-\. 00 .I~ N" 0 . . . .~C~~ . (D CD C) C> C) 0 0 C 0 - , ,C 0 00 NO c M l '"0 r- CO C) C O c D N'R cl Ii 0 C:> C> C C 0 ____6 t. c:> m 0 C54 WO 2012/162812 PCT/CA2012/000529 When patients that did not receive doxorubicin or daunorubicin were included, but received other anthracyclines, results were found (see Table 8). An assessment was also made to determine whether the definition of cardiotoxicity using a threshold of SFS26% influenced the results by performing a subgroup analysis of patients with more severe cardiotoxicity (SF<24% or symptoms, CTCAE grade 2-4). Again, similar results were obtained with comparable effect sizes (Table 9). Interestingly, in the combined cohort of severe cardiotoxicity, UGTlA6 rs17863783 now was significantly associated with ACT after correcting for multiple testing (P=1.1xl0-4; OR 6.22; P-corrected=0.036). TABLE 9. Association between SNPs and Anthracycline-Induced Cardiotoxicity Grade 2-4 Combined (n=462) 65 cases, 397 controls SNP rs-ID Gene Allele a OR (95% CI) P-value rs7853758 SLC28A3 A/G 0.37 (0.19 - 0.71) 9.6x10 rs885004 SLC28A3 A/G 0.36 (0.17 - 0.75) 0.0021 rs17863783 UGT1A6 A/C 6.22 (2.52 - 15.4) L.x10 -4 rs10426377 SULT2B1 A/C 0.58 (0.36 - 0.95) 0.024 rs2305364 SLC28Al A/G 1.99 (1.34 - 2.97) 5.6x10 rs4148350 ABCC1 A/C 1.89 (0.87 - 4.11) 0.12 rs1764570 HNMT G/A 0.77 (0.47 - 1.26) 0.29 rs9514091 SLC1OA2 A/G 0.70 (0.42 - 1.17) 0.16 rs4148808 ABCB4 A/G 1.79 (1.12 - 2.87) 0.018 rs17583889 HNMT A/C 1.88 (1.19 - 2.96) 0.0077 rs2290271 SLC28A1 C/A 0.54 (0.35 - 0.84) 0.0046 rs1736557 FMO3 A/G 0.18 (0.06 - 0.60) 3.5x10- 4 rs2019604 SPG7 C/A 0.46 (0.23 - 0.90) 0.014 rs7319981 SLCIOA2 A/G 0.72 (0.47 - 1.11) 0.13 rs4261716 UGT1A6 A/C 1.67 (1.12 - 2.47) 0.011 rs6759892 UGT1A6 C/A 1.65 (1.11 - 2.45) 0.013 rs2235047 ABCB1 C/A 1.91 (0.99 - 3.67) 0.064 rs4877847 SLC28A3 A/C 0.58 (0.39 - 0.87) 0.0078 rs729147 ADH7 G/A 1.59 (1.03 - 2.44) 0.038 rs 1149222 ABCB4 C/A 1.23 (0.80 - 1.90) 0.35 rs2108623 CYP4F11 G/A 0.77 (0.52 - 1.15) 0.20 rs316019 SLC22A2 A/C 0.71 (0.37 - 1.35) 0.28 Results from all cohorts combined. OR are per copy of the minor allele. aSNP alleles assayed; minor allele is mentioned first; P values in bold are significant after multiple testing correction; SNP, Single Nucleotide Polymorphism; OR, Odds Ratio; CI, Confidence Interval. A SNP replicated in this study was rs17863783, a synonymous variant (Val209Val) in UDP glucuronosyltransferase 1A6 (UGTlA6), which is known to glucuronidate several different substrates (Nagar, S. et al. Pharmacogenetics (2004) 14:487-499). This variant tags a specific haplotype (*4) in Europeans and East-Asians (not shown) that has been shown to have altered enzyme activity (Nagar, S. et 55 WO 2012/162812 PCT/CA2012/000529 al. Pharmacogenetics (2004) 14:487-499), although this effect might be substrate specific (Krishnaswamy, S. et al. J Pharmacol Exp Ther (2005) 313:1340-1346). Even though the doxorubicin and daunorubicin parent compounds are likely not glucuronidated, it has been shown that certain metabolites do undergo glucuronidation (Andrews, P.A. et al. Drug Metab Dispos (1980) 8:152-156). Thus altered glucuronidation might lead to accumulation of toxic anthracycline metabolites. Similarly, the replication of rs10426377 in SULT2B1 or sulfotransferase 2B1, which catalyzes the sulfate conjugation of many compounds (Ji, Y. et al. J Pharmacol Exp Ther (2007) 322:529-540), might be explained by altered sulfonation of anthracycline metabolites(Andrews, P.A. et al. Drug Metab Dispos (1980) 8:152-156). Previously, we showed the highly significant association of rs7853758 in SLC28A3 with ACT and further replication in a subset of the Dutch-EKZ cohort used in this study (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). Here, we further substantiated this finding as well as that of another SNP in SLC28A3 (rs885004) in an extended cohort. In addition, we now found additional, although not statistically significant (P-replication = 0.14; P-combined = 0.0020), evidence for association of rs2305364 in SLC28A1, which is structurally similar to SLC28A3 and has substantial substrate overlap (Pastor-Anglada, M. et al. Xenobiotica (2008) 38:972-994). Both SLC28A genes encode for concentrative nucleoside transporters, which can putatively transport several anthracyclines into cells (Nagasawa, K. et al. Curr Drug Metab (2001) 2:355-366). Evidence is presented herein for association of two variants in the ATP-binding cassette transporter B4 (ABCB4) in females only. ABC-transporters such as ABCB4 are known to efflux a variety of drugs including anthracyclines (Smith, A.J. et al. J Biol Chem (2000) 275:23530-23539). Reduced function or expression will lead to intracellular accumulation of anthracyclines. The strongest associated variant in ABCB4 (rs4148808) is located in the promoter region of the gene (Lang, T. et al. Drug Metab Dispos (2006) 34:1582-1599), potentially affecting expression. Female sex hormones likely reduce the expression of ABCB4 as well, as women with heterozygous mutations in ABCB4 can develop intrahepatic cholestasis during pregnancy when such hormones are high (Jacquemin, E. et al. Lancet (1999) 353:210-211), providing an explanation why an association was only seen in females. Similarly, the effect of SULT2B1 rs10426377 was observed in males only. While no differences in SULT2B 1 expression were found between male and female mice (Alnouti, Y. and Klaassen, C.D. Toxicol Sci (2006) 93:242-255), they do respond differently in SULT2B1 up-regulation after treatment with certain enzyme inducers (Alnouti, Y. and Klaassen, C.D. J Pharmacol Exp Ther (2008) 324:612-621). 56 WO 2012/162812 PCT/CA2012/000529 rs17583889, and to a lesser extent of rs17645700, in HNMT or histamine N-methyltransferase in younger children (<5.3 years) only. HNMT catalyzes the N-methylation of histamine thereby terminating its activity (Verburg, K.M. and Henry, D.P. Histamine N-Methyltransferase. In Boulton AA, Baker GB, Yu PH (eds): Neurotransmitter Enzymes, Edition Humana Press 1986; 147-204). In an experimental rat model of hypotension, central inhibition of HNMT, leads to activation of the histaminergic system and mobilization of compensatory cardiovascular mechanisms (Jochem, J. Inflamm Res (2004) 53:316-323). HNMT activity gradually increases in both mouse and rat brain after birth and in mouse kidney the activity is about 60 times higher at maturation then at birth (Laduron, P. et al. Naunyn Schmiedebergs Arch Pharmacol (1975) 286:379-387). In human red blood cells HNMT activity is correlated with age with younger age having lower activities (Scott, M.C. et al. Clin Pharmacol Ther (1988) 43:256-262), though no children under 5 years were included and no such correlation was seen in liver or renal samples (De Santi, C. et al. Xenobiotica (1998) 28:571-577). Nevertheless, in younger patients, in whom activity may be lower, the effects of variants might therefore have a greater impact. The exact mechanisms by which these variants affect ACT as well as validation of these potential heterogeneic effects will require future studies. The present studies were powered to find similar effect sizes, but often the effects are smaller in replication studies (Chanock, S.J. et al. Nature (2007) 447:655-660). Even though we have tried to keep the replication cohorts similar to the original cohorts, small differences might exist, for example in ethnicity, (supportive) treatment or follow-up and could potentially lead to non-replication due to different effects of the variants in specific populations or subgroups (Chanock, S.J. et al. Nature (2007) 447:655-660). In our analyses we corrected for the effects of several important clinical risk factors. Not unexpectedly, cumulative doses were statistically significant higher in cases compared to controls in both the Dutch EKZ and CPNDS cohort. Age was higher in CPNDS cases, whereas younger age is usually considered a risk factor (Kremer, L.C. et al. Ann Oncol (2002) 13:503-512). This is likely in part due to our requirement of controls to have at least 5 year follow-up, selecting for relatively younger controls in the CPNDS cohort. Population stratification could not be assessed in the current replication cohort as the number of SNPs included were insufficient to use principal component analysis to assess population structure (Visscher, H. et al. Pharmacogenomics J (2009) 9:362-372). However, in the original study cohorts, we calculated 57 WO 2012/162812 PCT/CA2012/000529 the genomic inflation factor to be 1.0 before principal component correction, indicating no population stratification and suggesting no or little influence on the results. The current risk prediction model based on replicated genetic variants and clinical factors improved the ability to discriminate between cases and controls compared to clinical factors alone (AUC 0.77 versus AUC 0.69). More importantly, this optimized model was replicated in our test cohort with similar metrics. Including these genetic factors to predict patients at high and low risk for ACT could therefore inform treatment options such as administering cardioprotective agents (e.g. dexrazoxane) or using alternative anthracycline dosing or formulations as well as change monitoring decisions which could lead to improved and safer anthracycline treatment. EXAMPLE 2 - EXTENDED PANEL CONTAINING 4,500+ SNPS Methods for EXAMPLE 2 Samples Study participants were recruited through the Canadian Pharmacogenomics Network for Drug Safety (CPNDS), a multicenter active surveillance consortium studying adverse drug reactions in children (Carleton, B. et al. Pharmacoepidemiol Drug Saf (2009) 18:713-721). The discovery cohort (n=344) in this study consisted of patients recruited from pediatric oncology units and long-term follow-up clinics across Canada between February 2005 and January 2010 and comprised of the two Canadian cohorts combined that were used previously to identify variants associated with ACT (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011). The replication cohort (n=218) consisted of additional patients recruited from across Canada between February 2010 and April 2011 and patients recruited at the Emma Children's Hospital/Academic Medical Centre in Amsterdam, the Netherlands, between July 2009 and April 2011 (van der Pal, H.J. et al. Arch Intern Med (2010) 170:1247-1255 ; and van Dalen, EC. et al. Eur J Cancer (2006) 42:3191-3198). This replication cohort was used previously to replicate earlier genetic findings and to validate the prediction model (Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011). The study cohorts and case-control defmitions have been described in detail elsewhere (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011; and Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT 1 A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011). In short, ACT cases were defined by early- or late-onset left ventricular dysfunction, during or after anthracycline treatment, on echocardiogram and/or symptoms requiring 58 WO 2012/162812 PCT/CA2012/000529 intervention based on CTCAEv3 (Cancer Therapy Evaluation Program - Common Terminology Criteria for Adverse Events - Version 3. In Edition 2003). To improve differentiation between cases and controls, a more stringent shortening fraction (SF) threshold of $26% was used for cases, while controls were required to have normal echocardiograms with SF30% during and at least 5 years after completion of anthracycline therapy. Transient acute cardiotoxicity was excluded by using only echocardiograms obtained >21 days after an anthracycline dose. Cumulative anthracycline doses were calculated using doxorubicin equivalents (Altman, A.J. Children's Oncology Group. Supportive care of children with cancer: current therapy and guidelines from the Children's Oncology Group. Baltimore: Johns Hopkins University Press 2004). Written informed consent or assent was obtained from each subject or their parents or legal guardians. The study was approved by the ethics committees of all participating universities and hospitals. Genotyping Genomic DNA was extracted from blood, saliva or buccal swabs using the QLAampTM DNA purification system (QiagenTM, Canada). DNA samples were genotyped for 4536 SNPs using a customized Illumina GoldenGateTM SNP genotyping assay (IlluminaTM, San Diego, USA), which was designed to capture the genetic variation of approximately 300 key drug biotransformation genes (i.e. phase I and II drug metabolism enzymes, drug transporters, drug targets, drug receptors, transcription factors, ion channels and other specific genes known to be related to the pathophysiological pathway of ADRs. This ADME (absorption, distribution, metabolism and elimination)-toxicity panel consisted of functional SNPs - that had been identified primarily by literature review and from public databases - that cause non-synonymous amino-acid changes or could be associated with changes in enzyme activity or function. In addition, tagSNPs were included that were identified using the ldSelectTM algorithm to select a maximally informative set of tagSNPs to assay the candidate genes (Carlson, C.S. et al. Am J Hum Genet (2004) 74:106-120). TagSNP selection was performed using data from phase II of the International HapMap project that included all four populations (CEU, CHB, JPT and YRI) (International HapMap Consortium. A haplotype map of the human genome. Nature (2005) 437:1299-1320) with a threshold for the linkage disequilibrium (LD) statistic r 2 of 0.8 and a minor allele frequency of >0.05. The current SNP panel is an updated version of the panel that was used previously (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011; Visscher, H. et al. Pharmacogenomics J (2009) 9:362-372; and Ross, C.J. et al. Nat Genet (2009) 41:1345-1349), which was extended to include additional genes and further optimized by replacing previously unsuccessful SNPs with others where possible or by optimizing the design of specific oligonucleotides. In addition, the main SNP panel was supplemented by a custom 96-SNP 59 WO 2012/162812 PCT/CA2012/000529 IlluminaTM Veracode GoldenGateTM genotyping assay. This assay was designed specifically to include both functional and tagSNPs in genes involved in the metabolism of anthracyclines into alcohol metabolites (AKRs and CBRs) (Blanco, J.G. et al. Cancer (2008) 112:2789-2795; Blanco, J.G. et al. J Clin Oncol (Meeting Abstracts) (2010) 28:9512; Bains, O.S. et al. Drug Metab Dispos (2008) 36:904 910; and Bains, O.S. et al. J Pharmacol Exp Ther (2010) 335:533-545) as well as other SNPs possibly related to ACT not included in the main panel. All SNP genotypes were manually clustered using IlluminaTM GenomeStudioTM software. Fifty-four SNPs were assayed in duplicate, so a total of 4578 unique SNPs were included. Furthermore, 374 SNPs that could not be clustered, or were non-polymorphic or had a completion rate of <95% as well as 51 ancestry-informative markers were excluded, leaving a total of 4153 SNPs for further analysis. The average call rate for the included SNPs was 99.8%. Concordance between replicate samples (n=34) was >99.9%. Sixteen samples (3 cases and 13 controls) with a call rate <95% were removed. The remaining 546 samples had an average call rate of 99.8%. Statistical analysis Hardy-Weinberg Equilibrium (HWE) tests were conducted using Fisher's Exact test in controls only. Twenty-nine SNPs had P<1.7x105 in the HWE test. These SNPs were marked, but retained in the analysis. All of the top associated SNPs were in HWE. To reduce possible false-positive associations due to multiple testing, we applied a tiered analysis to identify SNPs associated at P<0.01 in the larger discovery cohort that remained associated in the smaller replication cohort at P<0.05. A more conservative overall Bonferroni corrected significance threshold was calculated at P<1.7x1 0- using the effective number of independent tests (Mef,) (Gao, X. et al. Genet Epidemiol (2008) 32:361-369). No duplicate or (cryptic) related samples were found by calculating the average identity-by-state for each subject-pair. Population structure was assessed by principal component analysis. Our primary analysis was a case-control association test using logistic regression assuming an additive genetic model. Cumulative anthracycline dose was included, age at start of treatment, gender and radiation therapy to the heart as important clinical covariates and the first two principal components to correct for potential population stratification. As our primary aim was to identify additional variants, we also included the previously (Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT I A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011) validated variants in SLC28A3(rs7853758) and UGT1A6 (rs17863783) as covariates to adjust for the effect of these variants. Finally, the primary analysis was conducted in the 536 patients 60 WO 2012/162812 PCT/CA2012/000529 (125 cases an 411 controls) who received doxorubicin and/or daunorubicin as the effect of rs7853758 had previously only been observed in these patients (Visscher, H. et al. J Clin Oncol (2011) Epub 11 Oct 2011) - of these, 520 (122 cases and 398 controls) were successfully genotyped. Haplotypes were inferred using the expectation-maximization algorithm. Haplotype association tests were done using logistic regression and included the same covariates. Multivariate logistic regression models including multiple genetic variants and/or clinical variables were all trained in the discovery cohort and tested in the replication cohort as described previously (Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011). Risk scores were calculated by multiplying each variable with the estimated beta (log odds ratio) from the training cohort. To assess whether adding the newly identified variants to our previous model - that consisted of 5 SNPs as well as the clinical variables gender, age, anthracycline dose and radiation to the heart (Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline induced cardiotoxicity in children. Submitted to Cancer 2011) - would improve prediction of ACT, Receiver Operating Characteristic (ROC) curves were constructed and calculated the c-statistic (Area Under the Curve- AUC) using the risk scores from the model and the actual value (case or control). Statistical analyses were conducted using SNP and Variation SuiteTM 7.4.5 (Golden HelixTM, Bozeman, USA) and R 2.13.0 (R Development Core Team T M ) with package pROC 1.4.3 (Robin, X. et al. BMC Bioinformatics 2011; 12: 77). SLC22A17 and SLC22A 7 In a tiered analysis, two SNPs were identified, one located in the 3' region of solute carrier family 22, member 17 (SLC22A17;rs4982753) and another one in SLC22A7 (rs4149178), that were significantly associated with ACT in the discovery cohort (P=0.0078 and P=0.0034, respectively) and were confirmed in the replication cohort (P=0.0071 and P=0.047, respectively - TABLE 10). Both SNPs had similar effect sizes in both discovery and replication cohort with combined odds ratios (OR) of 0.50 (95% CI 0.33-0.75) and 0.45 (95% CI 0.26-0.75) respectively. Nearly identical results were obtained when we included patients that received other anthracyclines but not doxorubicin or daunorubicin (combined P=6.7x10-4 and P=9.4x10-4; OR 0.53 and OR 0.45, respectively). Again, in an analysis of only patients of European ancestry (99 cases, 314 controls), as determined by the first two principal components (Visscher, H. et al. Pharmacogenomics J (2009) 9:362 61 WO 2012/162812 PCT/CA2012/000529 372), results were similar with a combined OR for SLC22A17 rs4982753 of 0.57 (95% CI 0.37-0.88) and of 0.45 (95% CI 0.25-0.79) for SLC22A7 rs4149178. Finally, in a subgroup analysis of patients (64 cases) with more severe cardiotoxicity (SF<24% or symptoms, CTCAE grade 2-4), the result for SLC22A7 rs4149178 was comparable (OR 0.49 [95% CI 0.25-0.95]), while the effect for SLC22A17 rs4982753seemed less strong in this analysis [OR 0.73 (95% CI 0.44-1.20)]. We also genotyped several other variants in both genes; of these one other SNP in SLC22A1 7 (rsl 1625724) showed a marginal significant association with ACT (P=0.020, OR 1.63 in the combined cohort). To see whether this was due to LD between rs4982753 and this marker (r 2 =0.067), we adjusted for the effect of rs4982753 in SLC22A17 in the regression analysis. However, the effect of rsl1625724 did not completely disappear (P=0. 11, OR 1.40), suggesting an independent effect of this SNP. Interestingly, two other SNPs in SLC22A17 (rs12882406 and rs12896494) also became marginal significant after adjusting for the effect of rs4982753 (P=0.042 and P=0.031; OR 1.52 and OR 0.65, respectively). Haplotype analysis including these 4 SNPs did not reveal more significant results. Additional variants In addition to the variants in SLC22A1 7 and SLC22A7, suggestive evidence (P<0.005) was found for association of several other variants with ACT (see TABLE 11). Despite the fact that these variants were not identified in the tiered analysis were they significant after Bonferroni correction, it is likely that there are true associations between these SNPs and ACT. The strongest associated variant was rs10426628 (combined P=3.2xlO4, OR 1.92), which is located in sulfotransferase 2B 1 (SULT2B 1). As we had previously found evidence for association of another variant in SULT2B 1 with ACT (rs 10426377) see EXAMPLE 1, the analysis was re-run adjusting for the effect ofrs10426377. In this analysis, rs10426628 remained associated with ACT (combined P=0.0013, OR 1.80), suggesting an independent effect of this variant. Haplotype analysis revealed that the protective effect of the minor allele of rs10426377 (A) in carriers of haplotype AC (OR 0.41 [95% CI 0.26-0.66], P=7.4x10-5) and, to a lesser extent, the risk effect of the minor A-allele of rs10426628 in CA carriers (OR 2.04 [95% CI 1.38-3.03], P=4.4x10-4) was offset by the other allele in haplotype AA carriers (OR 1.50 [95% CI 0.72-3.11], P=0.29 - TABLE 12). Interestingly, many of the other variants with suggestive evidence (P<0.005) for association with ACT were found in genes related to oxidative stress (TABLE 11), which is important in ACT, indicating that these might be true associations. 62 WO 2012/162812 PCT/CA2012/000529 Predicdve model Next, we assessed whether adding the newly identified and replicated variants in SLC22A1 7 and SLC22A7 to the risk prediction model that was previously created discussed in EXAMPLE 1, would improve the ability to discriminate between cases and controls. ROC analyses showed that adding the two variants to the previous model did improve the AUC in the discovery cohort, in which the models were constructed, as well as in the replication cohort, in which the models were tested (TABLE 13). The AUC for the extended model in the combined cohort was 0.781 compared to 0.755 for the previous model (P=0.029). Similarly, in a genetic-only model (without the clinical variables included), adding the 2 SNPs improved the AUC significantly (0.716 vs. 0.671, P=0.0081; TABLE 14). TABLE 10. Discovery and replication of SNPs associated with anthracycine-induced cardiotoxicity Discovery (n-335) Replication (n=185) Combined (n=520) 78 cases, 257 controls 44 cases, 141 controls 122 cases, 398 controls SNP rs-ID Gene Chr Position' Typeb Allelesc OR (95% CI) P OR (95% CI) P OR (95% CI) P flanking/3' rs4982753 SLC22Al7 14 22,884,409 UTR A/G 0.52 (0.31-0.85) 0.0078 0.39 (0.19-0.81) 0.0071 0.50 (0.33-0.75) 4 .4xlO-4 rs4149178 SLC22A7 6 43,380,166 intronic G/A 0.41 (0.21-0.77) 0.0034 0.39 (0.14-1.05) 0.047 0.45 (0.26-0.75) 0.0013 SNPs associated with anthracycline-induced cardiotoxcity in discovery cohort at P<0.01 and validated in replication cohort at P<005. Results are from logistic regression analysis that included important clinical variables as well as the previously validated variants rs7853758 in SLC28A3 and rs17863783 in UGTlA6.[14] Only patients that did receive doxorubicin and/or daunorubicin were included Odds ratios are per copy of the minor allele. 'Position based on NCBI Build 36.3; 'Relative to gene of interest; 'SNP alleles assayed, minor allele mentioned first; SNP, Single Nucleotide Polymorphism; OR, Odds Ratio; CI, Confidence Interval. 63 WO 2012/162812 PCT/CA2012/000529 -W - - - - - -l -l - 0 - ~- - c ;- -c 0 0- 0) - 0 0n 0o 0 0 0 - -N 0c 0 C- 0 Co U O O O O0In0 O 0 0 0 ClO N 0 O(z0w u 7- N0 m N w N N N (a 0 r N N N N 'nl m W 00 tn CO'4 00 0 :r wO m m~ 00 ml m m r- r- ON Clr- O r O en F- .4 -r-5 C N kV 0 0 rn N N 00 N ~~ -6 ~ .- 0 - .- -~ - 00 0n 0 O 1 00 rq m 00 00Vn N-ON 00 -Cl 000 O k rl Ir - , =S N N , m N- t Ln ON 00 ml 0- ON 0m ON - 0 ~ N N NC Cl Cl 0q ON O N a*nt 000 00U t C4 o < n N 0 l0 0

-

N -. 0 - C ('~ 0 0- l ~ ~ Cl ~ 'n O C~ In c4 r4 C00 0 4 . 6666600 It 66~.6 0 Iibi N>NU c) kn m 0 . ON o V 'n V 00 C 00 -- 0 ON O C,=0 ON C. Lei ON4 - l C C-- - O N u 00 r ' ' 0 0 0 - N 6 6 - C 00 0 C - -c m na NON l N - C N ~ ' 00 r--C , 0 -: FC 0 V 0 00 m C"C l 0 0 C C /C ~ 1 0 l V ' 0 00....................... 6 6....................VNc 0' 0 u u ID 0 1 0 i 0 - 0 0 0 0 0- 00 000 4 t C C Cl ON 0 0 Cn rq Cl4 V l 00n VZ No 7q r- V)) ON.O 0 ,2C 0 ~ 1 > N'0 Z 00 V V r~ N ON V l 0 00 C 1 0 n 06O WO 2012/162812 PCT/CA2012/000529 TABLE 12. SULT2B1 haplotype analysis and anthracycline-induced cardiotoxicity Combined (n=520) 122 cases, 398 controls Haplotype Freq. cases Freq. controls OR (95% CI) P-value rs10426377-A rs10426628-G 0.14 0.25 0.41 (0.26-0.66) 7.4x10 5 rs10426377-C rs10426628-A 0.26 0.17 2.04 (1.38-3.03) 4.4 x10-4 rs10426377-A rs10426628-A 0.07 0.06 1.50 (0.72-3.11) 0.29 rs10426377-C rs10426628-G 0.53 0.52 0.97 (0.68-1.37) 0.85 Haplotype analysis of variants rs10426377 and rs10426628 in SULT2BI. Protection of rs10426377-A is offset by risk of rs 10426628-A in AA-carriers and vice versa. Haplotypes were inferred by EM-algorithm. Results are from logistic regression including clinical covariates. Odds ratios are per copy of the haplotype compared to all other haplotypes. Freq., haplotype frequency; OR, Odds Ratio; CI, Confidence Interval. TABLE 13. Comparison of different genetic only predictive models Discovery (n=335) Replication (n=185) Combined (n=520) P-value vs. 5 SNPs Model AUC 95% CI AUC 95% CI AUC 95% CI only 5 SNPs only 0.697 (0.630-0.763) 0.615 (0.524-0.705) 0.671 (0.617-0.724) - 5 SNPs only + SLC22A17 0.723 (0.658-0.787) 0.652(0.564-0.740) 0.700 (0.648-0.752) 0.018 5 SNPs only + SLC22A17 + 0.740 (0.678-0.803) 0.664 (0.579-0.750) 0.716 (0.666-0.766) 0.0081 SLC22A7 TABLE 14. Comparison of different predictive models Discovery (n=335) Replication (n=185) Combined (n=520) P-value Model AUC 95% CI AUC 95% CI AUC 95% CI vs. Clin-only vs. Previous Clinical only 0.681 (0.615-0.747) 0.663 (0.578-0.747) 0.676 (0.624-0.728) -- - Previous model (Clinical + 5 0.762 (0.701-0.823) 0.740 (0.659-0.821) 0.755 (0.706-0.804) 6.8x10~ 4

-

SNPs) Previous +4 SLC22A17 0.774 (0.716-0.833) 0.751 (0.673-0.828) 0.766 (0.719-0.813) 1.9 x104 0.16 Previous + SLC22A17+ 0.793 (0.737-0.849) 0.756 (0.684-0.829) 0.781 (0.737-0.826) 1.7 x10- 5 0.029 SLC22A7 Comparison of different models that were trained in the discovery and then tested in the replication cohort. P-values calculated for the combined cohort. The clinical only model included age, cumulative dose, gender, radiation therapy involving the heart region and the first two principal components. The previous model includes the same clinical variables as well as five SNPs (rs7853758, SLC28A3; rs17863783, UGTIA6; rs10426377, SULT2BI; rs2305364, SLC28A1; and rs4148808, ABCB4) from Visscher et al. [14]. The SNPs in SLC22A /7 (rs4982753) and SLC22A 7 (rs4149178) were subsequently added. AUC, Area Under the Curve; CI, Confidence interval. 65 WO 2012/162812 PCT/CA2012/000529 Comparison of different genetic only models that were trained in the discovery and then tested in the replication cohort. P values calculated for the combined cohort. The 5 SNPs only model includes five SNPs (rs7853758, SLC28A3; rsl 7863783, UGTJA6; rs10426377, SULT2BJ; rs2305364, SLC28AJ; and rs4148808, ABCB4) from Visscher et al. [14]. The SNPs in SLC22A17 (rs4982753) and SLC22A7 (rs4149178) were subsequently added. AUC, Area Under the Curve; CI, Confidence interval. Previously, several genetic variants were found to be associated with anthracycline-induced cardiotoxicity in children, though few have been replicated to date (Blanco, J.G. et al. Cancer (2008) 112:2789-2795; Rajic, V. et al. Leuk Lymphoma (2009) 50:1693-1698; Visscher, H. et al. J Clin 5 Oncol (2011) Epub 11 Oct 2011); and Visscher H, Ross CJ, Rassekh SR et al. Validation of SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Submitted to Cancer 2011). In the present example, we report the identification and replication of two additional variants in SLC22A17 and SLC22A7 as predictive markers of ACT. Additionally, evidence for association of variants in SULT2B 1 are shown as well 10 as in several antioxidant genes. Addition of the replicated variants to our ACT risk prediction model, further improved the ability of this model to predict patients at risk. The two identified and replicated variants were both found in a member of the solute carrier family 22. This large gene family currently consists of 26 members that encode for organic cation 15 transporters (OCTs), organic cation/camitine transporters (OCTNs), and organic anion transporters (OATs) (Koepsell, H. and Endou, H. Pflugers Arch (2004) 447:666-676; and Cano-Soldado, P. and Pastor-Anglada, M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med Res Rev (2011) published online: 1 FEB DOI: 10.1002/med.20221). Interestingly, two members of this family, SLC22A16(OCT6) and SLC22A4 20 (OCTNI), have recently been identified as importers of doxorubicin (Okabe, M. et al. Biochem Biophys Res Commun (2005) 333:754-762; and Okabe, M. et al. Mol Cancer Ther (2008) 7:308 1 3091). SLC22A17 or brain-type OCT, as it was first identified in brain, is an orphan transporter without a known endogenous substrate and is expressed in a variety of tissues including theheart as well as liver and kidney (Bennett, K.M. et al. Mol Cell Biochem (2011) 352:143-154). It shows 25 significant sequence similarity to many other OCTs, though differences do exist (Bennett, K.M. et al. Mol Cell Biochem (2011) 352:143-154). SLC22A7 or OAT2, which has been studied in more detail, is widely expressed including in cardiac tissue (Cropp, C.D. et al. Mol Pharmacol (2008) 73:1151-1158). It is able to transport naturally occurring nucleobases, nucleosides and nucleotides, with a preference for guanine analogs, and several nucleoside-based drugs and has considerable 30 substrate overlap with concentrative nucleoside transporters such as SLC28A3 (Cropp, C.D. et al. Mol Pharmacol (2008) 73:1151-1158; and Errasti-Murugarren, E. and Pastor-Anglada, M. Pharmacogenomics (2010) 11:809-841). Therefore, it seems plausible to that SLC22A17 and SLC22A7 are transporting anthracyclines. 66 WO 2012/162812 PCT/CA2012/000529 Furthermore, additional support was found for the involvement of SULT2B1 (rs10426628) in ACT. In combination with the independent association of rs10426377 set out in EXAMPLE 1, this provides compelling evidence for a role of genetic variants in SULT2B 1 in ACT risk. Interestingly, 5 inspection of these two intronic variants in the UCSC genome browser (http://genome.ucsc.edu/) revealed that they are located less than 200bp apart in a region with specific histone marks, DNase hypersensitivity and transcription factor binding which suggests putative enhancer activity (Heintzman, N.D. et al. Nat Genet (2007) 39:311-318), suggesting that these SNPs might affect SULT2B1 I expression. This sulfotransferase, which catalyzes the sulfate conjugation of many 10 compounds (Ji, Y. et al. J Pharmacol Exp Ther (2007) 322:529-540), may influence anthracycline metabolite sulfonation (Andrews, P.A. et al. Drug Metab Dispos (1980) 8:152-156), thereby affecting excretion of the drug and its toxic metabolites. Using a tiered analysis approach, the likelihood of finding false-positives (type I error) is reduced. 15 Clinical risk factors for ACT, such as cumulative dose and concomitant cardiac irradiation, will not have influenced our results, as they were included as covariates in the analysis. Furthermore, corrections for potential population stratification were made by including principal components in our analysis to reduce false-positives. Furthermore, we excluded cases with mild cardiotoxicity (SF;>27-30%) as well as controls with less than 5 years follow-up to ensure optimal separation 20 between cases and controls and increasing the chance to find true associations. Adding the variants in SLC22A1 7 and SLC22A7 improved the ACT risk prediction model significantly. 25 Risk stratification for anthracycline-induced cardiotoxicity based on a model that includes genetic risk variants, and not solely clinical risk factors, {COG Guidelines, 2008) might prove useful and could inform monitoring frequency to detect early damage {COG Guidelines, 2008) as well as indicate benefit of preventive measures such as use of cardio-protective agents (e.g. dexrazoxane) or alternative anthracycline dosing or formulations (Lipshultz, S.E. et al. Heart (2008) 94:525-533; van 30 Dalen, E.C. et al. Cochrane Database Syst Rev (2011) 6:CD003917; van Dalen, E.C. et al. Cochrane Database Syst Rev (2009) CD005008; and van Dalen, E.C. et al. Cochrane Database Syst Rev (2010) CD005006). Before clinical implementation of stratification based on genetic and clinical risk factors, future prospective studies will likely be needed to validate the current risk prediction model and to establish the benefit of such measures in these patients. The current results help to 35 further unravel genetic risk of ACT, thereby providing means to improve cancer therapy safety in children and potentially adults as well. 67

Claims (28)

1. A method of screening a subject having a neoplastic disease for cardiotoxicity risk, the method comprising: determining the identity for one or more of the following single 5 nucleotide polymorphisms (SNPs): rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628 or one or more polymorphic sites in linkage disequilibrium thereto, for the subject, wherein the subject is a candidate for anthracycline administration. 10

2. A method for diagnosing a predisposition for cardiotoxicity risk in a human subject from anthracycline administration, the method comprising: a) determining an identity for one or more of the following single nucleotide polymorphisms (SNPs) in a biological sample from the subject: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; 15 rs4148808; rsl149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs 10426628 or one or more polymorphic sites in linkage disequilibrium thereto from the sample; and b) making a cardiotoxicity risk determination based on the prevalence of risk alleles in the subject sample. 20

3. The method of claim 1 or 2, further comprising determining the identity of rs17863783 or one or more polymorphic sites in linkage disequilibrium thereto.

4. The method of claim 1, 2 or 3, wherein the anthracycline is selected from one or more of the following: anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), 25 doxorubicin, idarubicin, epirubicin, mitoxantrone, carminomycin, esorubicin, quelamycin, aclarubicin, esorubicin, zorubicin, pirarubicin, amrubicin, iododoxorubicin, detorubicin, marcellomycin, rodorubicin, and valrubicin.

5. The method of any one of claims 1-4, wherein the method further comprises administering 30 the anthracycline in accordance with the subject's risk of developing cardiotoxicity.

6. The method of any one of claims 1-5, wherein the subject has a cardiotoxicity risk allele selected from one or more of: rs7853758G; rs885004G; rs17863783A (reverse); rs17863783T (forward); rs10426377C; rs2305364A; rs4982753G (reverse); rs4982753C 35 (forward); rs4l49178A; and rs10426628A. 68 WO 2012/162812 PCT/CA2012/000529

7. The method of any one of claims 1-5, wherein the subject has a reduced cardiotoxicity risk allele selected from one or more of: rs7853758A; rs885004A; rs17863783C (reverse); rs17863783G (forward); rs10426377A; rs2305364G; rs4982753A (reverse); rs4982753T (forward); rs4149178G; and rsI0426628G. 5

8. The method of any one of claims 1-7, wherein the identity of a single nucleotide polymorphism is determined by one or more of the following techniques: (a) restriction fragment length analysis; (b) sequencing; 10 (c) micro-sequencing assay; (d) hybridization; (e) invader assay; (f) gene chip hybridization assays; (g) oligonucleotide ligation assay; 15 (h) ligation rolling circle amplification; (i) 5' nuclease assay; (j) polymerase proofreading methods; (k) allele specific PCR; (1) matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass 20 spectroscopy; (in) ligase chain reaction assay; (n) enzyme-amplified electronic transduction; (o) single base pair extension assay; and (p) reading sequence data. 25

9. A method of determining cardiotoxicity risk from anthracycline administration, the method comprising: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs885004; rs17863783; rs10426377; and rs2305364; or a polymorphic sites in linkage disequilibrium thereto, for a subject receiving 30 or about to receive one or more anthracyclines.

10. A method of determining cardiotoxicity risk from anthracycline administration, the method comprising: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs4148808; rs17863783; rs10426377; and 35 rs2305364; or a polymorphic sites in linkage disequilibrium thereto, for a subject receiving or about to receive one or more anthracyclines. 69 WO 2012/162812 PCT/CA2012/000529

11. A method of determining cardiotoxicity risk from anthracycline administration, the method comprising: determining the identity of the single nucleotide polymorphism (SNP) at each of the following polymorphic sites: rs7853758; rs17863783; rs10426377; and rs2305364; or 5 a polymorphic sites in linkage disequilibrium thereto, for a subject receiving or about to receive one or more anthracyclines.

12. The method of claim 9, 10, or 11, further comprising determining the identity of the following two SNPs: rs4982753; and rs4149178; or one or more polymorphic sites in 10 linkage disequilibrium thereto.

13. The method of any one of claims 9-12, wherein the anthracycline is selected from one or more of the following: anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), doxorubicin, idarubicin, epirubicin, mitoxantrone, carminomycin, esorubicin, 15 quelamycin, aclarubicin, esorubicin, zorubicin, pirarubicin, amrubicin, iododoxorubicin, detorubicin, marcellomycin, Rodorubicin, and valrubicin.

14. The method of any one of claims 7, wherein the method further comprises administering the anthracycline in accordance with the subject's risk of developing cardiotoxicity. 20

15. The method of any one of claims 9-12, wherein the subject has a cardiotoxicity risk allele selected from one or more of: rs7853758G; rs885004G; rs17863783A (reverse); rs17863783T (forward); rs10426377C; rs2305364A; rs4982753G (reverse); rs4982753C (forward); rs4149178A; and rs10426628A. 25

16. The method of any one of claims 9-12, wherein the subject has a reduced cardiotoxicity risk allele selected from one or more of: rs7853758A; rs885004A; rs17863783C (reverse); rs17863783G (forward); rs10426377A; rs2305364G; rs4982753A (reverse); rs4982753T (forward); rs4l49178G; and rs10426628G. 30

17. The method of any one of claims 9-16, wherein the identity of a single nucleotide polymorphism is determined by one or more of the following techniques: (a) restriction fragment length analysis; (b) sequencing; 35 (c) micro-sequencing assay; (d) hybridization; 70 WO 2012/162812 PCT/CA2012/000529 (e) invader assay; (f) gene chip hybridization assays; (g) oligonucleotide ligation assay; (h) ligation rolling circle amplification; 5 (i) 5' nuclease assay; (j) polymerase proofreading methods; (k) allele specific PCR; (1) matrix assisted laser desorption ionization time of flight (MALDI-TOF) mass spectroscopy; 10 (m) ligase chain reaction assay; (n) enzyme-amplified electronic transduction; (o) single base pair extension assay; and (p) reading sequence data. 15

18. Two or more oligonucleotides or peptide nucleic acids of about 10 to about 400 nucleotides that hybridize specifically to a sequence contained in a human target sequence consisting of a subject's toxicity associated gene sequence, a complementary sequence of the target sequence or RNA equivalent of the target sequence and wherein the oligonucleotides or peptide nucleic acids are operable in determining the presence or absence of two or more 20 polymorphism(s) in the toxicity associated gene sequence selected from of the following polymorphic sites: rs7853758; rs885004; rs17863783; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rs1149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628. 25

19. Two or more oligonucleotides or peptide nucleic acids selected from the group consisting of: (a) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:1 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:1 having a G at position 301; 30 (b) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 1 having a G at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 1 having an A at position 301; (c) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:2 having a G at position 201 35 but not to a nucleic acid molecule comprising SEQ ID NO:2 having an A at position 201; 71 WO 2012/162812 PCT/CA2012/000529 (d) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:2 having an A at position 201 but not to a nucleic acid molecule comprising SEQ ID NO:2 having an G at position 201; (e) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 5 conditions to a nucleic acid molecule comprising SEQ ID NO:3 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:3 having a C at position 301; (f) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:3 having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:3 having an A at position 301; 10 (g) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:4 having an A at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:4 having a C at position 501; (h) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:4 having a C at position 501 15 but not to a nucleic acid molecule comprising SEQ ID NO:4 having an A at position 501; (i) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:5 having an A at position 251 but not to a nucleic acid molecule comprising SEQ ID NO:5 having a G at position 251; (j) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 20 conditions to a nucleic acid molecule comprising SEQ ID NO:5 having a G at position 251 but not to a nucleic acid molecule comprising SEQ ID NO:5 having an A at position 251; (k) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:6 having an A at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:6 having a G at position 501; 25 (1) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:6 having a G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:6 having an A at position 501; (in) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:7 having an A at position 401 30 but not to a nucleic acid molecule comprising SEQ ID NO:7 having a G at position 401; (n) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:7 having a G at position 401 but not to a nucleic acid molecule comprising SEQ ID NO:7 having an A at position 401; (o) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 35 conditions to a nucleic acid molecule comprising SEQ ID NO:8 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:8 having a G at position 301; 72 WO 2012/162812 PCT/CA2012/000529 (p) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:8 having a G at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:8 having an A at position 301; (q) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 5 conditions to a nucleic acid molecule comprising SEQ ID NO:9 having an A at position 201 but not to a nucleic acid molecule comprising SEQ ID NO:9 having a C at position 201; (r) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:9 having a C at position 201 but not to a nucleic acid molecule comprising SEQ ID NO:9 having an A at position 201; 10 (s) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 10 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:10 having a C at position 301; (t) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 15 conditions to a nucleic acid molecule comprising SEQ ID NO:10 having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:10 having an A at position 301; (u) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 11 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 11 having a C at position 20 301; (v) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 1l having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:1 1 having an A at position 301; (w) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 25 conditions to a nucleic acid molecule comprising SEQ ID NO: 12 having an A at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 12 having a T at position 301; (x) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO: 12 having a T at position 301 30 but not to a nucleic acid molecule comprising SEQ ID NO:12 having an A at position 301; (y) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:13 having a C at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:13 having a G at position 501; (z) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 35 conditions to a nucleic acid molecule comprising SEQ ID NO:13 having a G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO: 13 having a C at position 501; 73 WO 2012/162812 PCT/CA2012/000529 (aa) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:14 having a C at position 301 but not to a nucleic acid molecule comprising SEQ ID NO:14 having a T at position 301; (bb) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 5 conditions to a nucleic acid molecule comprising SEQ ID NO: 14 having a T at position 301 but not to a nucleic acid molecule comprising SEQ ID NO: 14 having a C at position 301; (cc) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:15 having an A at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having a C, G, or T at 10 position 501; (dd) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:15 having a C at position 501 but not to a nucleic acid molecule comprising SEQ ID NO: 15 having an A, G, or T at position 501; 15 (ee) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency conditions to a nucleic acid molecule comprising SEQ ID NO:15 having an G at position 501 but not to a nucleic acid molecule comprising SEQ ID NO:15 having a C, A, or T at position 501; and (ff) an oligonucleotide or peptide nucleic acid that hybridizes under high stringency 20 conditions to a nucleic acid molecule comprising SEQ ID NO:15 having a T at position 501 but not to a nucleic acid molecule comprising SEQ ID NO: 15 having an A, G, or C at position 501.

20. An array of oligonucleotides or peptide nucleic acids attached to a solid support, the array 25 comprising two or more of the oligonucleotides or peptide nucleic acids of claim 18 or 19.

21. A composition comprising an addressable collection of two or more oligonucleotides or peptide nucleic acids, the two or more oligonucleotides or peptide nucleic acids consisting essentially of two or more nucleic acid molecules set out in SEQ ID NO:1-15 or 30 compliments, fragments, variants, or analogs thereof.

22. The oligonucleotides or peptide nucleic acids of claim 18 or 19, further comprising one or more of the following: a detectable label; a quencher; a mobility modifier; a contiguous non target sequence situated 5' or 3' to the target sequence or 5' and 3' to the target sequence. 35

23. A use of an anthracycline compound having a cardiotoxicity risk in the manufacture of a 74 WO 2012/162812 PCT/CA2012/000529 medicament for the treatment of a subject, where the subject is a candidate for anthracycline administration, and wherein the subject treated has a reduced cardiotoxicity risk genotype at one or more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl149222; rs17583889; rs4877847; 5 rsl 1625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto.

24. A use of an anthracycline compound having a cardiotoxicity risk for the treatment of a subject, wherein the subject treated has a reduced cardiotoxicity risk genotype at one or 10 more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rs11625724; rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto; for the subject, where the subject is a candidate for anthracycline administration. 15

25. The use of claim 23 or 24, wherein the subject has a reduced cardiotoxicity risk genotype at rs17863783 or one or more polymorphic sites in linkage disequilibrium thereto.

26. Anthracyclines for use in a method of treating a neoplastic disease in a subject in need there 20 of, the method comprising: (a) selecting a subject having a reduced risk of developing cardiotoxicity, wherein cardiotoxicity is based on the identity of a single nucleotide polymorphism (SNP) at one or more of the following polymorphic sites: rs7853758; rs885004; rs10426377; rs2305364; rs4982753; rs4149178; rs4148808; rsl 149222; rs17583889; rs4877847; rsl 1625724; 25 rs12882406; rs12896494; and rs10426628; or one or more polymorphic sites in linkage disequilibrium thereto; and (b) administering said subject one or more anthracyclines.

27. The anthracycline of claim 26, wherein the subject also has a reduced cardiotoxicity risk 30 genotype at rs17863783 or one or more polymorphic sites in linkage disequilibrium thereto.

28. The anthracycline of claim 26 or 27, wherein the anthracycline is selected from one or more of the following: anthracycline antibiotics such as daunorubicin (daunomycin, rubidomycin), doxorubicin, idarubicin, epirubicin, mitoxantrone, carminomycin, esorubicin, 35 quelamycin, aclarubicin, esorubicin, zorubicin, pirarubicin, amrubicin, iododoxorubicin, detorubicin, marcellomycin, Rodorubicin, and valrubicin. 75